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ABSTRACT 
 
 
PREPARING WHOLE GENOME HUMAN MITOCHONDRIAL DNA LIBRARIES 
FOR NEXT GENERATION SEQUENCING USING ILLUMINA® NEXTERA® XT 
Hilde Stawski, B.S. 
Western Carolina University (December 2013) 
Director: Dr. Mark R. Wilson 
 
Forensic DNA casework principally relies on the analysis of short tandem repeats 
(STRs) from nuclear DNA (nDNA). In cases where nDNA may not be suitable for 
analysis (i.e., highly degraded DNA or DNA present in quantities too low to obtain an 
STR profile), mitochondrial DNA (mtDNA) is an excellent alternative. MtDNA is a 
circular genome of approximately 16.5 kb, is maternally derived, and is present in 
thousands of copies per cell versus two copies of nuclear DNA. The combined higher 
copy number, circular shape of the genome and protection by the double membrane of 
the mitochondrion allows for a greater probability to recover sufficient mtDNA for typing 
of degraded samples. 
Presently, forensic analysts sequence two or three hypervariable (HV) regions 
found in the non-coding control region of the mtGenome, since sequencing of the entire 
mitochondrial genome (mtGenome) is rather costly and labor-intensive. Additionally, 
difficulties sequencing through homopolymeric regions, as well as the presence of low-
level mixtures in samples, can add complexity to the analysis of mtDNA in casework 
when traditional Sanger sequencing methods are used. These issues can be addressed 
 
 
with Next Generation Sequencing (NGS) technologies. NGS enables deeper analysis of 
the genome for identification of low-level mixtures, since clonal populations of 
molecules originating from a single template strand are sequenced. Moreover, this 
technology allows for the more cost-effective sequencing of whole mtGenomes compared 
to Sanger methods, since more sequences are obtained for the same sample. By 
expanding mtDNA analysis to the entire mtGenome, a better resolution in distinguishing 
between haplotypes is established. 
In forensic casework, amplification of challenging samples such as hair and aged 
bone is often performed differently than that of reference samples (buccal swabs, blood, 
etc.) due to the higher possibility of DNA degradation and limited mtDNA 
concentrations. For this study, two sample preparation approaches were developed 
including one method for robust reference samples, and one method for forensically 
relevant challenging samples.   
For NGS analysis of reference samples, DNA was extracted from buccal swabs 
obtained from eight donors. A long PCR approach, which refers to the amplification of 
DNA fragments of a size that may not be amplified using conventional PCR reagents, 
was successfully performed on these DNA extracts using a highly processive polymerase 
mixture and novel primer pairs to amplify the mtGenome in two independent PCR 
reactions, with overlap at the noncoding region. These samples were subsequently 
processed with Illumina® Nextera® XT. This NGS library preparation kit is designed 
exclusively for use with Illumina® instrumentation and employs an engineered 
Transposome™ to randomly fragment and tag amplicons and small genomes with 
Illumina® specific adapters. After library preparation, samples were sequenced on the 
 
 
Illumina® MiSeq™. This method generated whole mtGenome NGS data, which 
accurately reflected the Sanger sequence. 
For analysis of challenging samples, DNA was extracted from 2 cm fragments of 
hair shafts from a subset of the same donors, using an optimized DNA extraction 
protocol.  Whole genome amplification (WGA) was performed on these extracts with 
four different commercially available WGA kits. WGA allows for pre-amplification of 
the entire mtGenome without the need for any additional primer design, after which the 
resulting DNA can be used for downstream applications. This potentially provides the 
forensic analyst with an increase in DNA template, resulting in a higher possibility of 
obtaining useful data from a casework sample. The increase in mtDNA copy number was 
assessed with a human mtDNA specific qPCR assay. A subset of the samples before and 
after WGA was amplified using a targeted multiplex PCR approach. This product, in 
addition to a subset of WGA product that was not PCR amplified after WGA, was 
prepared with Illumina® Nextera® XT and sequenced on the Illumina® MiSeq™.  
This research effort generated a protocol for obtaining whole mtGenome NGS 
data from reference samples such as buccal swabs. In addition, preliminary data was 
generated for future studies designed to obtain whole mtGenome NGS data from 
challenging sample types. 
 
 
 
 
1 
 CHAPTER 1: INTRODUCTION 
 
 
1.1 Forensic Human Identification  
 
 When a crime has been committed, samples are obtained from the crime scene 
and sent to the forensic laboratory. In a typical case, a Known (K) sample is taken from 
an individual, usually in the form of a buccal swab, and the results from the DNA 
analysis are compared to the Questioned (Q) samples found at the crime scene. 
Afterward, a statement is made as to whether or not the donor of the K sample could have 
contributed the Q sample.  
 When possible, analysis is performed on nuclear DNA (nDNA). This 3.3 billion 
base pairs (bp) long chromosomal DNA resides in the nucleus and is present in two 
copies per cell. It recombines during meiosis before it is passed down from both parents 
to their children. In the early stages of human identification, Dr. Alec Jeffreys discovered 
long repeating sequences in the nDNA and investigated these by performing Restriction 
Fragment Length Polymorphism (RFLP) studies. This technique employs enzymes that 
cut the DNA at designated sites, which shows a particular pattern upon size separation by 
gel electrophoresis (Jeffreys, Wilson, and Thein 1985).  
 Currently, forensic DNA casework largely relies on the analysis of short tandem 
repeats (STRs) from nDNA. These short DNA sequence repeats occur in abundance 
throughout the non-coding regions of the nuclear genome (Kimpton et al. 1993). In 
casework, the STRs are amplified with primers that are appended with fluorescent dyes, 
and the resulting amplicons are separated by size with capillary electrophoresis to 
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determine the variation in repeats between individuals (Collins et al. 2004). Since nDNA 
recombines in a loci-independent manner, it is very suitable for human identification 
because this allows for combining the results for all STR loci. By doing so it is possible 
to establish identity from a DNA sample.  
 In some cases, STRs may not be suitable for analysis (i.e. highly degraded 
DNA, or DNA present in quantities too low to obtain an STR profile). This is often the 
case with hairs and aged teeth and bone samples. In these instances, mitochondrial DNA 
(mtDNA) is an excellent alternative method of DNA analysis. Unlike nDNA, mtDNA is 
maternally inherited, which limits its resolution to a maternal lineage. However, this 
feature makes it particularly useful in kinship testing and the identification of human 
remains.  
 The mitochondrial genome (mtGenome) resides in the mitochondria of a cell. It 
is circular, approximately 16.5 kb long and is present in thousands of copies depending 
on the cell type, compared to the two copies of nDNA in a single cell (Budowle et al. 
2003, Bogenhagen and Clayton 1974). Because of its smaller size, the total amount of 
mtDNA in a cell is lower than that of the nDNA, but its higher copy number, its shape 
and the extra level of protection from the environment provided by the double membrane 
of the mitochondrion increases the level of sensitivity and allows for a greater probability 
of recovering sufficient mtDNA for typing of degraded samples (Foran 2006).  
 Due to its maternal inheritance, the evidentiary value of mtDNA differs from 
that of nDNA; it cannot be used to establish identity. Since there is no recombination of 
the mtDNA, all maternal relatives have the same profile, apart from germ-line mutations 
that may have arisen.  
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 When mtDNA sequence data is obtained from a questioned sample, it is 
compared to a reference sequence, currently the revised Cambridge Reference Sequence 
(rCRS) (Anderson et al. 1981), and variants from the reference are reported. The variants 
obtained for the K sample are then compared to those of the Q sample to determine 
whether or not the K sample could have contributed to the mtDNA profile of the Q 
sample (Figure 1) and are scored as follows (Budowle, Wilson and DiZinno, 1999): 
1.  “Cannot be excluded” if the Q sample and K sample have a common base at each 
position. This includes low-level mixed positions, which present as a mixture of 
nucleotides at the same position that arise due to mutations. 
2.  “Inconclusive” if there is one single-nucleotide polymorphism (SNP) difference 
between the Q sequence and the K sequence. 
3. “Excluded” if there are two or more SNP differences. 
 If the known sample cannot be excluded as a potential source of the questioned 
sample, a statistical interpretation of the frequency of its haplotype in an mtDNA 
population database is given to provide a weight assessment for the DNA evidence. A 
population database is a collection of mtDNA sequences that have been observed in the 
population, which can be clustered in haplogroups depending on their patterns of 
common ancestry (Budowle et al. 2003). For example, for an “H1a1b” haplotype the 
“1a1b” designation refers to a particular sub-type identified within the “H” haplogroup. 
  
Figure 1: Different interpretations in mtDNA casework. Left: one SNP difference between Q and 
K, inconclusive. Middle: no differences, cannot be excluded. Right: common variant from the 
rCRS shared by Q and K, cannot be excluded. 
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Figure 2: Structure of the mitochondrial genome (Taylor and Turnbull 2005). The hypervariable 
regions make up less than 4% of the entire mtGenome. Red boxes: HVI (left), HVII (right). 
 
 The mitochondrial genome itself is categorized into a coding and a non-coding 
region. As the name implies, the coding region codes for certain genes (Figure 2). The 
non-coding control region (D-loop) of the mtGenome mutates at a higher rate than the 
coding region (Greenberg, Newbold, and Sugino 1983, Parsons et al. 1997). This allows 
forensic DNA analysts to focus their analysis on two or three hypervariable (HV) regions 
found in the D-loop, which contain the most inter-individual variation.  
 Sequencing of the entire mtGenome with traditional sequencing methods 
(detailed in section 1.1.1) is labor intensive, and can require large amounts of DNA 
 
 
5 
(Holland MM, Parsons TJ 1999, de Vries et al. 2012). Although it has been shown to 
allow for a better resolution in distinguishing between haplotypes (Andréasson et al. 
2007) this type of analysis is typically not performed. A higher degree of resolution is 
desirable in mtDNA casework, as this provides the DNA analyst with more data to 
provide enhanced resolution of haplotypes. The introduction of Next Generation 
Sequencing  (NGS) instruments, which combine many sequencing reactions at once and 
allow for more data to be obtained from DNA samples, renders whole mtGenome 
sequence analysis more feasible. NGS is explained in detail in section 1.1.2. 
 In addition, NGS methods may assist in the identification of DNA mixtures 
and/or heteroplasmy, which is the existence of two or more mtDNA sequences in one 
individual (Salas, Lareu, and Carracedo 2001). Both length heteroplasmy - different 
lengths of a sequence motif - as well as sequence heteroplasmy, which manifests as more 
than one base at the same position, occur in mtDNA (Budowle et al. 2003, Salas, Lareu, 
and Carracedo 2001). The degree to which sequence heteroplasmy can be identified with 
traditional sequencing methods is limited (Holland MM, Parsons TJ 1999). The estimated 
limit of detection using currently employed methods is approximately 10% (Wilson et al. 
1995).  
 
1.1.1 Sanger Sequencing 
 
 Traditionally, mtDNA sequence analysis is accomplished using PCR followed 
by Sanger sequencing (Sanger, Nicklen, and Coulson 1977). With this technique the 
amplified DNA template is terminated at different base positions, which ultimately 
allows for the visualization of each base position in a sequence.  
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 In one application of Sanger sequencing, a single forward or reverse primer is 
annealed to the template and extended with deoxyribonucleotide triphosphates (dNTPs) 
and four individual dideoxyribonucleoside triphosphates (ddNTPs) that are fluorescently 
labeled with four different fluorophores. A ddNTP terminates the extension of a DNA 
strand because it lacks a hydroxyl group on the 3’ carbon to which the next dNTP is 
added. Termination occurs randomly at all base positions, resulting in the creation of 
fluorescently labeled fragments of different lengths (Figure 3). This technique is currently 
combined with capillary electrophoresis-based separation of the labeled fragments 
(Sanger, Nicklen, and Coulson 1977). 
 
 
Figure 3: Sanger sequencing results in the formation of fluorescently labeled fragments of 
different lengths (Butler 2005). 
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1.1.2 Next Generation Sequencing 
 
 NGS, also called massively parallel sequencing, is a technique that combines 
hundreds of thousands, or on some platforms even millions, of individual sequencing 
reactions simultaneously (Metzker 2010, Shendure and Ji 2008). Large volumes of data 
are obtained by imaging the sequencing reactions in real-time.  
 By introducing NGS technology into the crime laboratory, more information 
can be obtained from the same DNA sample. With Sanger sequencing, a sequence is 
usually covered by one forward and one reverse “read”. A read count, or coverage, 
defines how many times a DNA strand has been sequenced. With NGS technologies, 
thousands of independent reads overlap at each position, and therefore more data points 
are obtained from the same position. Thus, bases are sequenced at a higher depth, which 
increases the ability to detect heteroplasmy and/or mixtures (Figure 4). Previous studies 
have shown that mixtures occurring at a rate as low as 1.3-1.6% can be reliably detected 
with NGS, which is significantly lower than the aforementioned 10% with Sanger 
sequencing (Yiping He et al. 2010, Tang et al. 2013).  
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Figure 4: Differences in read depth in Sanger sequencing vs. NGS. Green: forward reads. Red: 
reverse reads. Additional data points are obtained using NGS due to the parallel processing of 
many more reads. 
 
 NGS significantly reduces the cost of sequencing (Wetterstrand KA). Although the 
initial instrument purchase and reagents can be quite expensive, they are used more 
efficiently (Liu et al. 2012, Loman et al. 2012). By incorporating short oligos of known 
sequence into the DNA molecules of each sample (indexing) the sequence data from each 
sample can be recognized during data analysis. Thus, individual sequence data from 
many samples can be processed simultaneously (multiplexing). This reduces the overall 
cost per sample, although the number of samples that can be processed is dependent on 
how many indices can be used in the same run. As stated previously, many more reads 
can be obtained for a DNA sample with NGS, which not only facilitates the sequencing 
of DNA in a higher degree of depth, but also breadth: more sequencing data can be 
 
 
9 
obtained across the genome. These two factors make the expansion of analysis to the 
entire mtGenome much more feasible on NGS systems as compared to Sanger 
sequencing.  
 There are several other differences between current NGS technologies and 
Sanger sequencing: sequence chemistry, read length, sequence time and sequence 
accuracy (Loman et al. 2012, Jünemann et al. 2013). The following bench top NGS 
platforms are popular in the scientific community, but many other systems also exist. The 
Roche® 454 GS Junior™, which measures light emission after base incorporation, can 
sequence up to 500 consecutive bases. The Ion Torrent™ PGM™ measures fluctuations 
in pH that are influenced by base incorporation, and can reach read lengths of 400 bp. 
The Illumina® MiSeq™ is based on the incorporation of fluorescent bases (further 
explained in section 1.3). Its current read length is 2x300 base pairs (300 bases forward 
and reverse). These maximum read lengths are shorter than that of traditional Sanger 
sequencing, which can generate up to 1000 bases of sequencing data (Shendure and Ji 
2008). However, as stated before, NGS allows for sequencing at a higher breadth and 
depth than Sanger sequencing since more data points are obtained in one run. 
 In addition to chemistry and read length, NGS differs from Sanger sequencing in 
run time. Sequencing can take from several hours to several days, depending on the 
platform (Loman et al. 2012). Although this is significantly longer than Sanger 
sequencing runs, which typically last no more than a few hours (Liu et al. 2012) it is 
important to again note that one NGS run can result in many more data points than a 
Sanger run.  
 The raw base accuracy of the NGS instruments can be lower than capillary 
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electrophoresis instruments. For example, the Roche® 454 GS Junior™ shows higher 
rates of substitutions, insertions and deletions when sequencing through homopolymeric 
stretches (Loman et al. 2012). When identical nucleotides are incorporated 
simultaneously, the emitted light signal does not linearly increase with the number of 
consecutive bases in these stretches, which can cause ambiguity in length determination. 
However, because NGS technology provides deeper coverage and since these systems 
employ algorithms for error correction, these issues can be partially circumvented (Jeck 
et al. 2007, Kao, Chan, and Song 2011, Meacham et al. 2011).  
 
1.2 Illumina® MiSeq™ 
 
 This study focuses on the Illumina® MiSeq™ instrument. The general 
workflow for analysis on the MiSeq™ includes library preparation, single molecule 
amplification by bridge PCR and reversible terminator sequencing-by-synthesis 
(Shendure and Ji 2008). 
 Libraries are DNA fragments from the target sequence that are appended with 
adapter sequences. These adapters are necessary so that the target DNA will bind to 
complementary oligonucleotides that are bound to the surface of the reaction chamber, 
which is where the sequencing chemistry takes place; on the Illumina® MiSeq™ this 
surface is called a flow cell. This MiSeq™ flow cell is an optically transparent reaction 
chamber, which allows for the detection of fluorescence emanating from bound DNA 
sequences. The process of library preparation is detailed in section 1.3. Although other 
library preparations are available, this study focuses on Illumina® Nextera® XT, a 
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method that is commercially available through Illumina®. 
 After binding of the libraries to the flow cell, each anchored oligo is extended; 
the incorporated bases are complementary to the bound DNA template (Figure 5A). This 
double stranded DNA is denatured and the original strand is washed away, leaving only 
the covalently anchored libraries. Bridge PCR (bPCR) is then used to clonally amplify 
each single bound DNA molecule (Bentley et al. 2008).  
 
 A                    B           C 
 
Figure 5: Bridge PCR and preparation of libraries for Illumina® sequencing (Illumina® 2011). A: 
Libraries attach and are immobilized after which the strands are extended in the 3’ direction. B: 
Bridge PCR is performed, creating clusters of each single DNA molecule. C: Strands are 
linearized and all 3’ ends are blocked prior to sequencing.  
 
 The opposing end of each synthesized strand hybridizes to complementary lawn 
primers, forming a bridge (Figure 5B). Primers are added and extended, after which the 
resulting DNA strands are denatured. Hybridization and extension steps are repeated 
throughout multiple cycles, generating a so-called “cluster” of approximately a thousand 
copies from a single DNA molecule. All fragments of the original template are amplified 
and hybridized in this way, resulting in billions of individual sequences generated in 
parallel (Shendure and Ji 2008, Metzker 2010). 
 Bridge PCR is followed by reversible terminator sequencing-by-synthesis. This 
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process starts with denaturation of the clusters, after which the reverse strands are cleaved 
off to leave ssDNA fragments bound to the flow cell (Figure 5C). Then, the 3’ ends of the 
remaining forward strands and the unused flow cell-bound oligos are blocked with 
ddNTPs by a terminal transferase. Sequencing primers are then added, and hybridized to 
the immobilized fragments. These sequencing primers are extended by one base with 
fluorescently labeled dNTPs, which are complementary to the template bound to the flow 
cell. These dNTPs are blocked with a 3′-O-azidomethyl blocking group (Figure 6A) 
(Bentley et al. 2008). The labels are excited with a laser and emit light signals at defined 
wavelengths depending upon on the incorporated, complementary, nucleotide.  
 
                A                 B 
Figure 6: Reversible terminator sequencing-by-synthesis on Illumina® systems (Illumina® 
2010). A: DNA template is extended with fluorescently labeled nucleotides, one nucleotide 
position at a time. B: Fluorescent signal from clusters is imaged by a CCD camera in real-time. 
 
 The next sequencing cycle starts with cleavage of the fluorophore and blocking 
group by tris(2-carboxyethyl)phosphine (TCEP) from the dNTP, followed by a wash to 
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remove used reagents, after which the template DNA is extended by the next dNTP 
(Mardis 2008). The fluorescence from all clusters on the flow cell is measured by a 
charge-coupled device (CCD) (Figure 6B).  
 The Illumina® MiSeq™ instrument features paired-end sequencing. After 
sequencing in the forward direction is complete, one round of bridge amplification is then 
performed, and the opposing end of the DNA fragments are hybridized to the flow cell. 
This allows for the reverse strand of the DNA fragment to then be sequenced, resulting in 
a doubling of the length that can be sequenced from each cluster (Figure 7) (Glenn 2011). 
 
Figure 7: Single-end vs. paired end sequencing (Glenn 2011). F indicates forward read, R 
indicates reverse read. A single-end run is only comprised of one read, whereas a paired-end run 
sequences the DNA molecule from both strands in separate, linked, reads. 
 
1.3 Illumina® Nextera® XT Library Preparation 
 
 As stated previously, the initial step in the NGS workflow is library preparation. 
The library consists of DNA target molecules with adapters, such that they are able to 
hybridize to the reaction chamber of the NGS instrument, the flow cell in the case of the 
Illumina® MiSeq™. 
 In one application, targeted amplification with modified primers: these primers 
include adapter sequences at the 5’ ends, and the resulting amplicons can be directly 
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hybridized. Other strategies for library preparation have also been developed. Among 
these is the fragmentation of long strands of template DNA prior to addition (ligation) of 
the adapters. 
 There are several methods of fragmenting DNA molecules to prepare libraries 
for NGS. Fragmentation of DNA occurs by focused acoustics, nebulization or enzymatic 
digestion. Focused acoustics shears DNA by implementing acoustic wave energy, which 
results in the formation and collapse of air bubbles that causes the breakage of DNA 
strands (Voelkerding, Dames, and Durtschi 2010). These types of instruments require a 
significant starting investment, and are therefore less feasible for smaller laboratories. 
Nebulization is a more inexpensive technique, which harnesses the force of compressed 
air to shear DNA. However, this method is more prone to sample loss and cross-
contamination (Voelkerding, Dames, and Durtschi 2010, Liu 2011). 
 Another less costly and less contamination-prone alternative to library 
preparation is enzymatic digestion. Different NGS platforms require different fragment 
sizes, and hence an advantage of enzymatic fragmentation techniques over nebulization 
or sonication is that the fragment size can be more easily controlled. One example 
includes NEBNext® dsDNA Fragmentase®, a dual enzyme system. The first enzyme 
randomly nicks the DNA, the other enzyme then recognizes the nick and cuts the 
opposite side of the strand, resulting in random fragmentation (Liu 2011, Knierim et al. 
2011).  
 Fragmentation using some of the techniques mentioned previously result in 
terminal overhangs on the DNA fragments. These require repair by end blunting, or 
filling the terminal overhang with its complementary base. This, depending on the NGS 
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platform, may then be followed by addition of a single adenine base to the 3’ ends 
(monoadenylation) so the adapters, which have a thymine overhang, can be ligated to the 
DNA fragment (Voelkerding, Dames, and Durtschi 2010, Liu 2011). 
 These processes of DNA fragmentation, end repair and adapter ligation can be 
very time consuming. By contrast, Illumina® Nextera® XT is a library preparation 
method that may potentially simplify the library preparation process. Nextera® XT has 
been developed for library preparation of small genomes and PCR amplicons (Illumina® 
2012). It is based upon the Nextera® system that can be used to prepare larger genomes 
for sequencing.  
 Nextera® XT employs a Transposome™ complex, consisting of a transposon 
with free ends and a transposase enzyme (Marine et al. 2011). Transposons are genetic 
elements capable of cutting and pasting themselves into different locations in the genome 
(Campbell and Reece 2004). They typically contain a gene that codes for the transposase 
enzyme, which catalyzes the reaction. Nextera® XT uses a mutated form of the Tn5 
transposase, which has a higher activity than the wild type enzyme (Adey et al. 2010). 
This Nextera® XT enzyme fragments the DNA template and covalently tags the 5’ ends 
with Illumina® specific sequencing primer sequences that are on the transposon 
(“tagmenting”) during a five-minute reaction (Figure 8A, B). To add the necessary index 
sequences and flow cell adapters to the DNA fragments, a 12-cycle Polymerase Chain 
Reaction (PCR) is performed. Indices can be used to separate fragments for analysis 
following the completion of the run (Metzker 2010). After incorporation of these indices 
and adapters, the library preparation process is complete (Figure 8C) (Adey et al. 2010). 
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Figure 8: Illumina® Nextera® XT tagmentation and limited cycle PCR (Illumina® 2012). A: 
transposome with sequencing sites on the transposon ends (green and blue). B: DNA has been 
fragmented and tagged with sequencing sites. C: Top, limited-cycle PCR with primers specific to 
sequencing sites (blue and green), index (purple) and adapter sequences (orange and red). 
Bottom: completed DNA library. 
 
 After the 12-cycle PCR reaction, the DNA fragments are then size-selected with 
Agencourt® AMPure® XP beads. These paramagnetic beads select DNA molecules of 
different sizes based on altering the ratio of beads to DNA molecules; a higher ratio 
changes the electrostatic properties of the beads and thus allows for the binding of 
smaller DNA molecules, and vice versa (DeAngelis, Wang, and Hawkins 1995). Then, 
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the libraries are normalized in concentration with another magnetic bead-based 
technique, which attempts to ensure that all samples generate approximately the same 
amount of sequencing data. The DNA is bound to the beads, washed and eluted, after 
which the libraries can be pooled and sequenced (Illumina® 2012).  
 Advantages of the Illumina® Nextera® XT system are that it can be used to 
prepare complete DNA libraries from samples containing 1 nanogram of DNA in under 
four hours (Illumina® 2012). It follows a simple protocol with a significantly smaller 
amount of hands-on time than traditional library preparation methods.  
 With other methods, manual size selection with gel electrophoresis and 
quantification of the library prior to sequencing is necessary. Presently, the bead-based 
size selection in Nextera® XT does not require any additional visualization, although it is 
recommended that single-stranded DNA be quantified prior to sequencing. 
 Since indices are added to both sides of the DNA fragment, several samples 
may be multiplexed and run on the Illumina® MiSeq™ system simultaneously. As such, 
high-coverage data, which is necessary for reliable minor variant and mixture detection, 
can quickly be obtained. Thus, Illumina® Nextera® XT would make a useful system to 
employ in forensic laboratories, which need to sequence samples quickly, efficiently and 
accurately. 
 
1.4 Bioinformatics 
 
 Bioinformatics, the science of collection and analysis of all biological data with 
computer software, is an important part of NGS since appropriate data handling is crucial 
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to proper interpretation. During sequencing, Illumina®’s Real Time Analysis (RTA) 
software performs base calling. In addition, Sequencing Analysis Viewer (SAV) outputs 
certain quality metrics of the sequencing run, such as the number of clusters generated, 
the intensity of the fluorescent signal, and quality (Q) scores of each base. These Q-
scores are based on a logarithm of error probability at a certain position (Cock et al. 
2010). For example, a score of Q30 indicates a 0.1% probability of an incorrect base call; 
lower Q scores indicate lower base accuracy (Table 1) (Minoche, Dohm, and 
Himmelbauer 2011). 
 
Table 1: Quality scores as pertaining to base accuracy. 
Quality score Error probability Base accuracy 
10 1/10 bases 90% 
20 1/100 bases 99% 
30 1/1,000 bases 99.9% 
40 1/10,000 bases 99.99% 
 
 After completion of the sequencing process, MiSeq™ Reporter (MSR), an on-
board software package, performs secondary analysis (Illumina® 2013a). MSR 
demultiplexes the data, which means that the pool of sequence data from a run is 
separated by reading the short index sequences and then placed into distinct bins. FASTQ 
files are then generated, which contain both base calling information as well as the 
corresponding Q-scores for each base (Cock et al. 2010). In the case of the resequencing 
workflow in MSR, which is used for sequencing targets with a known reference 
sequence, the sequence reads in the FASTQ files are aligned to the reference.  
 In this workflow in MSR, alignment is performed by the Burrows-Wheeler 
Aligner (BWA) which aligns short reads to a reference while allowing short gaps and 
 
 
19 
mismatches (Li and Durbin 2009). BWA is a global aligner, which considers the 
complete read for successful alignment. Additional alignment algorithms are available in 
MSR including a banded Smith-Waterman algorithm. This is a local aligner, which 
considers different fragment sizes of each read during alignment.  
 If a reference sequence is used, then variants from the reference are called in the 
final step of the MSR workflow. In MSR, this is performed with either Genome Analysis 
Toolkit (GATK) (McKenna et al. 2010) or with Illumina®’s Somatic Variant Caller, 
which is able to detect low-level variants from a reference if proper thresholds are 
specified.  
 In addition to MSR, there are many other options available to analyze NGS 
data. Numerous bioinformatics tools are currently available, e.g. the Blat-Like Fast 
Accurate Search Tool (BFAST) for alignment (Homer, Merriman, and Nelson 2009). 
These tools can be installed directly onto a computer and controlled by typing commands 
into the command line interface (CLI). These command line tools give the user a very 
broad assortment of settings to design a custom pipeline suited to the type of information 
that needs to be gleaned from their sequence data (Kumar and Dudley 2007). 
 Integrative Genomics Viewer (IGV) is a Java-based freeware package 
developed by the Broad Institute, which provides the user with a Graphical User Interface 
(GUI) for simple implementation of commands. IGV can be used to view Sequence 
Alignment/Map (SAM) or Binary SAM (BAM) files, which are used to store read 
alignments in a smaller file size (Li et al. 2009), or Variant Call Format (VCF) files, 
which consist of variants from the rCRS extracted from an alignment file (Danecek et al. 
2011). This software is particularly useful for scrolling through large sets of reads. 
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Visualization of data can be very helpful; IGV is fast, which allows the user, among other 
things, to observe the overall coverage throughout the genome, zoom in on the sequence 
to the nucleotide level and identify the location of low-level variants (Figure 9). 
 
Figure 9: Visualization of a whole human mitochondrial genome dataset in IGV. Shown is 
sequence from base 1 to 8,000. Coverage is shown in gray, with variants from the reference 
sequence marked as narrow colored bars. Below, forward and reverse reads are indicated in red 
and blue, respectively, with deletions marked as black dashes. 
 
 Commercial software packages, such as CLC bio® CLC Genomics Workbench 
(CGW), offer a complete GUI-driven solution from importing a FASTQ file to creating 
alignments and calling variants. Compared to using command line tools, this commercial 
software package may limit control over parameters to simplify data analysis and 
increase user-friendliness. In addition, CGW is installed locally which, if a high-
performance computer is used, can provide a tremendous increase in computing power 
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over cloud-based analysis software that depend on internet speed (CLC bio 2012). The 
integrated workflow option in CGW allows the user to create and save analysis pipelines 
so the same set of analyses can quickly be applied to several data sets. These features 
make CGW a powerful software package. 
 CGW encompasses many tools for different types of analyses, including Sanger 
sequencing and NGS of both RNA and DNA. The CGW software can be used to output 
extensive reports on data quality and metrics, and features a number of methods to 
visualize data. For NGS analysis CGW incorporates a custom alignment algorithm that 
supports local alignment. Variant calling can be performed with the Quality-based 
Variant Detection (QVD) tool, which calls variants from a reference based on the quality 
scores of the putative variant and its surrounding sequence. In contrast, the Probabilistic 
Variant Detection (PVD) tool calls variants based on a custom algorithm that combines 
Bayesian statistics and an estimation of Maximum Likelihood.  
 
1.5 Whole Mitochondrial Genome Sequencing 
 
 As mentioned previously, Sanger sequencing is a relatively labor-intensive as 
well as expensive tool to analyze entire mtGenomes. NGS allows for sequencing of 
multiple human mtGenomes by massively parallel sequencing of short fragments of DNA 
(Pareek, Smoczynski, and Tretyn 2011). Thus, analysis of the mtGenome can be 
expanded outside of the HV regions, which encompass less than 4% of the entire 
molecule (Coble et al. 2004). Sequencing the whole mtGenome provides the forensic 
analyst with more data, which increases the exclusionary power of mtDNA. For example, 
from a group of 60 individuals that exhibited no or a single SNP variant from the rCRS in 
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the HV regions, 80% of individuals could be resolved when the analysis was expanded to 
the entire mtGenome (Andréasson et al. 2007). However, mtDNA population databases 
like EMPOP (Parson and Dür 2007) need to be broadened to incorporate whole genome 
reference sequences to obtain robust estimates of mtGenome rarity from casework 
analyses (Irwin et al. 2011).  
 This study is focused on the analysis of mtDNA in two distinct sample types:  
1. Buccal swabs, which usually contain pristine DNA, can be easily amplified using a 
“targeted” PCR, or amplification performed on a specific region of the genome. The 
approach described in this study employs longer primer sets to encompass the entire 
mtGenome, which can be rapidly sequenced with NGS to generate data for reference 
purposes or the analysis of known samples.  
2. Hair shaft extracts, a challenging sample type that often contains degraded DNA, are 
traditionally amplified with multiple shorter primer sets. For whole mtGenome 
sequencing, this can pose a limitation as these hair shaft extracts contain low 
concentrations of mtDNA. To reliably sequence hair shaft extracts with NGS, mtDNA in 
these samples may be pre-amplified, meaning that the total DNA template in a sample is 
amplified using a non-specific approach. The targeted PCR and pre-amplification 
techniques mentioned above will be discussed in detail in the following sections.  
1.5.1 Long PCR - Targeted Amplification 
 
 The long PCR (LPCR) performed in this study is a targeted amplification that 
employs mtDNA specific primers to ensure mtDNA in the reference sample is amplified 
and available for NGS. Two primer sets were designed to create two amplicons of 9.1 
and 11.1 kb in two separate reactions; these amplicons overlap at the control region in 
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order to generate double sequence coverage in this region (Figure 10). This LPCR 
requires largely intact DNA, and thus can be used on robust sample types such as blood 
or buccal swabs to generate whole mtGenome reference sequences. A similar dual-primer 
set long PCR approach has successfully been implemented on high quality mtDNA 
extracted from buccal swabs (Gunnarsdóttir et al. 2011) and blood samples (Fendt et al. 
2009).  
 The TaKaRa™ Long and Accurate system was chosen to perform this LPCR 
amplification. TaKaRa™ consists of a mixture of a Taq polymerase and a proofreading 
polymerase with 3 ́-5 ́ exonuclease activity. This system has a fidelity 6.5 times higher 
than conventional Taq polymerase, and is routinely used to generate amplicons up to 25, 
(Goto, Nishino, and Hayashi 2006) and amplicons as large as 50 kb have been reported 
(Seki, Hayashida, and Shinozaki 1996). 
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Figure 10. Long PCR performed with two primer sets. This results in a 9065 bp amplicon and an 
11170 bp amplicon. 
 
 Conventional Taq polymerases show a higher rate of base misincorporation than 
other types of polymerases. If base mismatches occur at priming sites, these may cause 
the polymerase to stall during extension (Huang, Arnheim, and Goodman 1992, Barnes 
1994). Because the proofreading enzyme in the TaKaRa LA Taq™ system removes 3’ 
bases, this Taq polymerase is less likely to stall, and thus longer amplicons can be 
generated (Davies and Gray 2002). 
1.5.2 Whole Genome Amplification - Pre-amplification 
 
 Hairs are a typically challenging sample type found in forensic casework. The 
amount of cell nuclei in a hair shaft is extremely limited and can vary from individual to 
individual, which adds to the difficulty of extracting nuclear DNA from hairs (Szabo et 
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al. 2012). Thus, it is more feasible to extract small quantities of mitochondrial DNA from 
hair shafts. These extracts often contain degraded mtDNA, and they therefore require 
amplification with shorter primer sets to successfully generate an amplicon. As hair shaft 
extracts are often limited in mtDNA copy number, it is less feasible to generate whole 
mtGenome sequences from these samples by PCR amplification alone. Potentially, 
Whole Genome Amplification (WGA), a technique initially developed for random 
amplification of the entire genome (Dean et al. 2002) can overcome this issue by creating 
more DNA template from an extract. This pre-amplified material may then be used to 
generate more PCR amplicons around the mtGenome. These amplicons can then be 
sequenced to generate whole mtGenome NGS data from challenging sample types.  
Some WGA methods are performed at a constant temperature (isothermal), 
whereas others are based on PCR. Multiple Displacement Amplification (MDA) is one of 
several isothermal WGA methods. This technique employs a Ø29 bacteriophage DNA 
polymerase to extend random hexamer oligos during an isothermal reaction. This 
polymerase has 3’ -> 5’ proofreading activity and is capable of generating DNA strands 
of 70,000 base pairs and higher (Blanco et al. 1989). Some MDA methods can yield up to 
a 100,000-fold increase in genomic DNA. 
During an MDA reaction, random hexamers anneal to the template DNA and are 
extended (see Figure 11). Upon encountering a previously extended strand, the Ø29 
polymerase displaces that strand and continues copying the template DNA. Ergo, the 3’ 
ends of the strands displace 5’ ends of other, adjacent, strands that are extended in the 
same direction. Primers anneal to these newly synthesized strands and are extended in the 
reverse direction as well. This process results in the creation of a branched network of 
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amplified DNA molecules (Schneider et al. 2004). As stated previously, as this is not a 
targeted amplification, the generated DNA template is non-specific. 
 
 
Figure 11: Strand displacement during whole genome amplification (Spits et al. 2006). 1-2: 
Primers anneal randomly and are extended. 3-4: Extending strands displace existing strands, 
while additional hexamer primers anneal and are extended in parallel. 
 
 Sigma-Aldrich® GenomePlex® is a PCR-based WGA method. This method 
incorporates a series of steps to fragment the DNA template, after which universal 
adapters are ligated to the fragments. These adapters subsequently facilitate PCR 
amplification with a single universal primer (Figure 12). Traditional MDA reactions have 
shown to exhibit an amplification bias (preferential amplification of certain loci over 
others) less than 3-fold. This is significantly lower than many PCR-based WGA methods, 
which have exhibited amplification bias up to 103 – 106 fold (Dean et al. 2002). However, 
the GenomePlex® method, as opposed to other PCR-based WGA methods, has not 
shown to introduce any significant amplification bias when compared to an MDA method 
(Barker et al. 2004). 
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Figure 12: Overview of the GenomePlex® technique (Sigma-Aldrich®). DNA is fragmented, 
after which primers are annealed and extended. The product is then amplified with a single 
primer. 
 
 WGA techniques should be evaluated in two categories: efficiency and 
accuracy. 
1. Efficiency: in order to positively affect downstream processes the method should 
sufficiently amplify the starting material in hair shaft extracts. It has been shown 
that some WGA methods do not perform well in this respect when limited starting 
material is present. In some cases, the primers have been known to branch off 
each other (hyperbranching), which creates large quantities of non-specific, 
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primer-derived material (Barber and Foran 2006, Lage et al. 2003). This can 
cause issues in downstream analyses, both in sequencing (low amounts of target 
sequence present) as well as quantification (overestimation of target material 
concentration when using non-specific quantification methods). 
2. Accuracy: the method used should accurately amplify the starting material. Due to 
the high clonal amplification by WGA methods, base misincorporations are a 
concern, especially with the introduction of very sensitive NGS technologies. 
Even small base misincorporations may ultimately affect the mtDNA 
interpretation in casework.  
 In this research effort, four different commercially available WGA kits were 
evaluated to compare their efficacy and accuracy in amplifying mtDNA from hair shaft 
extracts. Due to its high amplification efficiency and accuracy, the MDA technique is 
promising, as shown in studies cited above. It has been noted that the MDA technique 
does not seem to perform as well on degraded DNA, due to a lower probability of primer 
annealing, as binding sites may have been fragmented (Barber and Foran 2006). In 
addition, primers are not likely to consistently bind near the ends of the fragments. Thus, 
primer extension may e.g. start in the middle of a DNA fragment, which creates an 
extension product half the size of the original fragment. As the DNA may be further 
fragmented during amplification, the activity of the enzyme is not optimally utilized. 
However, this study employs an optimized hair extraction protocol, which may improve 
the quality of extracted DNA and potentially facilitate more efficient amplification using 
the MDA method. Moreover, even a small fold amplification may be sufficient for 
effective sequencing using NGS, since the Illumina® Nextera® XT library preparation 
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technique requires only 1 ng input of double-stranded template DNA.  
 Three isothermal MDA kits were used in this study: the QIAGEN® REPLI-g 
Mini kit, Mitochondrial DNA kit and Single Cell kit. The Mini kit is optimized for >1 ng 
of input DNA, whereas the Mitochondrial DNA kit employs mtDNA-specific hexamers 
in addition to random hexamers, and the Single Cell kit is optimized for sample inputs as 
low as a single cell (QIAGEN® 2011a, QIAGEN® 2011b, QIAGEN® 2012a). 
 One PCR-based kit was chosen to compare the efficiency of a PCR-based 
method to MDA methods. The Sigma-Aldrich® GenomePlex® kit was selected since it 
is one of a few PCR-based WGA methods that has not shown to introduce any significant 
amplification bias when compared to an MDA method (Barker et al. 2004). Furthermore, 
in a comparison between seven different WGA kits, the GenomePlex® kit was deemed to 
be the best when using degraded starting material, since mtDNA typing subsequent to 
WGA was successful even for DNA that was fragmented to 100 bp (Maciejewska, 
Jakubowska, and Pawłowski 2013). Additionally, this kit may be useful since the initial 
fragmentation step in the protocol can be omitted in cases of potential fragmentation of 
the DNA template, such as with hair shaft extracts. This may theoretically generate larger 
DNA fragments than the MDA method applied to degraded samples, as explained 
previously. 
 
1.6 Mitochondrial DNA Quantification 
 
 Assessing the quantity of mitochondrial DNA in samples is critical to this study; 
by quantifying the amount of mtDNA in hair samples before and after WGA, it is 
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possible to calculate how well WGA has pre-amplified the mtDNA in these samples. This 
was assessed using real-time PCR, with a sensitive 5’ nuclease assay specific to human 
mtDNA (Kavlick et al. 2011). Real-time PCR (rtPCR or qPCR) is a technique often used 
to quantify DNA. The qPCR performed in this study is a 5’ nuclease assay, which 
employs primers and probes designed for a specific target sequence (Heid et al. 1996). 
 Probes are short target-specific DNA sequences which hybridize to the template 
DNA between the forward and reverse primer during the annealing step of the qPCR 
(Heid et al. 1996). A nonfluorescent quencher (NFQ) and a minor groove binder (MGB) 
are attached to the 3’ end of the probe, and a fluorescent reporter dye is attached at the 5’ 
end. When the probe is bound to the template, the reporter and quencher are in close 
proximity, which prevents the reporter dye from emitting fluorescence. However, during 
primer extension the polymerase degrades the probe, which releases the reporter dye and 
results in fluorescence.  
 Since this is a PCR-based technique, the DNA template accumulates during 
amplification. A CCD camera in the qPCR instrument is used to detect the increasing 
amount of fluorescence generated by the quencher. When this fluorescence crosses a 
predetermined threshold, the instrument notes the cycle number during which this occurs 
and assigns a cycle threshold (CT) value to the sample. The CT values for the samples can 
be compared to those of the standard curve, which allows for determination of the 
mtDNA copy number in a sample. As with all 5’ nuclease assays, the human mtDNA 
qPCR assay used in this study is sensitive, and can accurately detect a quantity of 
mitochondrial DNA in a sample ranging from 10 to 108 copies (Kavlick et al. 2011). 
QPCR also applies an internal positive control (IPC) assay that uses separate IPC 
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primers, DNA and a probe to verify whether the reagents and the instrument are working 
properly and to detect the presence of inhibitors (Honeycutt, Sobral, and McClelland 
1997). 
 
1.7 Objectives 
 
 The present research effort studies the preparation of mtDNA in reference and 
forensic sample types for NGS, and aims to fulfill three goals: 
 1. To establish a method for the targeted amplification and NGS of mtDNA 
from reference samples. Buccal swabs usually contain pristine DNA, which can be 
amplified using a long PCR approach and rapidly sequenced with NGS to establish whole 
mtGenome reference sequence for comparison purposes. Due to the amount of data that 
can be obtained with NGS, many samples can be run at once, depending on how many 
indices are employed. 
 2. To evaluate the use of different Whole Genome Amplification techniques on 
forensic sample types such as hair or bone. These are traditionally more difficult to 
analyze, since they often contain degraded DNA and are limited in mtDNA copy number. 
Therefore, these samples may require amplification with shorter primer sets. Potentially, 
WGA can overcome this limitation by creating more DNA template molecules from the 
same sample. In addition, with NGS the limit of detection of minor variants in mixtures is 
lowered compared to that of Sanger sequencing, allowing an enhanced detection of 
mixed samples. 
 3. To evaluate Illumina® Nextera® XT technology for mtDNA library 
preparation and subsequent Illumina® MiSeq™ sequencing in a forensic context. Library 
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preparation is an important step in NGS, since the appropriate amount of clusters need to 
be generated for a run to be successful. In addition, library preparation should allow for 
accurate sequencing of DNA samples. For use in forensic laboratories, the method should 
be simple and fast and should allow for the multiplexing of several whole mtGenomes in 
one run while generating high-coverage data. The Illumina® Nextera® XR method was 
evaluated by preparing different sample types for sequencing; WGA product, of which a 
subset was additionally PCR amplified prior to sequencing, and long PCR products were 
prepared with this kit and sequenced on the Illumina® MiSeq™ in two separate 
sequencing runs. This study fills a gap in present knowledge, as prior to this research no 
studies have been published that combines this particular NGS library preparation 
technique with forensic human mtDNA analysis.  
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CHAPTER 2: MATERIALS AND METHODS 
 
 
The flow chart below (Figure 13) illustrates the two different pathways that were taken in 
this study for analysis of reference samples and challenging samples.  
 
Figure 13: Experiments performed for reference samples and challenging samples. 
 
 MtDNA research is highly prone to contamination, and therefore requires the 
analyst to maintain pristine laboratory conditions. For each experiment, all objects in the 
laminar flow hood were cleaned with 10% bleach and 70% ethanol, after which the hood 
was UV irradiated for 15 minutes. Any reagents that do not hold biological material, such 
as sterile water and TE buffer, as well as any other items necessary for the experiment 
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such as 1.5 ml Eppendorf tubes, optical plates or caps, were UV irradiated for 15 minutes 
either in the laminar flow hood or in a Spectrolinker® XL-1000 UV Crosslinker. During 
the experiment, the analyst’s hair was tied back and they wore a laboratory coat, 
facemask, a pair of gloves under a set of disposable sleeves and a pair of gloves over it. 
The outer gloves were renewed upon suspected contamination. 
 
2.1 Collection of Reference Material  
 
 Buccal swabs, hairs and whole blood delivered directly on Whatman™ FTA™ 
cards were obtained from eight donors according to approved Institutional Review Board 
(IRB) protocol.  
 DNA was extracted from the buccal swabs using the Qiagen® QIAamp® DNA 
Mini Kit™ (QIAGEN® 2012b) according to the manufacturer’s instructions, and eluted 
in 150 µl TE buffer.  
 From the FTA™ cards, 1.2 mm punches were taken with a Whatman™ Harris 
Micro Punch, which were then washed using vendor’s protocol (Whatman), for a total of 
eight washes with Whatman™ FTA™ Purification Reagent. 
 
2.2 Creation of Reference Sequences with Sanger Sequencing  
 
 DNA extracted from buccal swabs, as described in section 2.1, was used to generate 
whole mtGenome reference data using the Applied Biosystems® mitoSEQr™assay, 
which employs 46 primer pairs to PCR amplify the entire mtGenome (Applied 
Biosystems® 2006). The concentration of nuclear DNA in these extracts was quantified 
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with the Applied Biosystems® Quantifiler® Human DNA Quantification kit on an 
Applied Biosystems 7500 Real-Time PCR System according to vendor’s protocol 
(Applied Biosystems®). The extracts were then diluted to 1 ng/µl.  
 
2.2.1 Amplification with AmpliTaq Gold® 
 
To PCR amplify the DNA in the donor samples, reactions were set up as shown in Table 
2, for each of the 46 primer pairs.  
Table 2: Reaction conditions for the Applied Biosystems® mitoSEQr™assay with AmpliTaq 
Gold® 
Reagent µ l/reaction Final concentration 
DNA Template (1 ng/µl)* 1 - 
Primer Pair 2 60 nM each 
AmpliTaq Gold® PCR Master Mix (2x) 5 1x 
50% glycerol 1.6 5% 
Sterile water 0.4 - 
Total volume 10 - 
*In addition to 1 ng/µl diluted buccal swab extracts, for the amplification of five amplicons 
across two donors 1.2 mm punches from whole blood samples stored on FTA™ cards were used. 
In these cases, 1 µl of additional sterile water was added to the reaction mixture, as FTA™ 
punches are not considered to add volume to the PCR reaction. 
 
 The same reaction conditions were used for the extraction reagent blank and a 
positive control.  For the reagent blank, water was taken through the extraction process, 
while for the positive control, 1 ng of purified genomic DNA from Applied Biosystems® 
was amplified with one randomly chosen primer pair from the set of 46 and one primer 
pair that was held consistent throughout all amplifications. This genomic DNA was 
provided to the Forensic Science program at Western Carolina University by Applied 
Biosystems® and is not commercially available. Amplification was performed under the 
thermal cycling conditions shown in Table 3 using an Applied Biosystems® Veriti® 96-
Well thermal cycler. 
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Table 3: Thermal cycling conditions for the Applied Biosystems® mitoSEQr™assay with 
AmpliTaq Gold® 
 
96°C for 5 min  
94°C for 30 s 
40 cycles 60°C for 45 s 
72°C for 45 s 
72°C for 10 min  
4°C hold  
 
2.2.2 Amplification with Roche FastStart™ 
 
 Repeated amplification issues were seen with approximately 36 primer sets across 
five donors. Troubleshooting these issues by changing the DNA template from buccal 
swabs to punches from blood FTA cards, as well as extracting fresh buccal swabs, 
allowed for successful amplification of some, but not all, amplicons. For the remaining 
12 primer sets across four donors it was decided to alter the master mix. For these 12 
primer sets the AmpliTaq Gold® master mix was substituted with Roche FastStart™ 
reagents (Table 4). 
 
Table 4: Reaction conditions for the Applied Biosystems® mitoSEQr™assay with Roche 
FastStart™. Conditions were altered as compared to Table 2, due to master mix requirements for 
the FastStart™ enzyme. 
 
Reagent µ l/reaction Final concentration 
FastStart High Fidelity Reaction 
Buffer 10x, with 18 mM MgCl2 
2.5 1x, 1.8 mM MgCl2 
DMSO 2.5 10 % 
dNTP Mix, 10 mM each 0.5 200 µM each 
FastStart High Fidelity Enzyme 
Blend 0.25 1.25 U 
Primer mix 8.4 0.2 µM each 
DNA template (1 ng/ul) 1 - 
Sterile water 9.85 - 
Total volume 25 - 
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 Again, the same conditions were used for the extraction reagent blank and 1 ng of 
Applied Biosystems® genomic DNA. Amplification was performed as per Table 5 on an 
Applied Biosystems® Veriti® 96-Well thermal cycler. Due to the expected higher 
activity of the Roche FastStart™ enzyme as compared to the AmpliTaq Gold® master 
mix, the number of PCR cycles was lowered in comparison to the usual mitoSEQr™ 
protocol. 
Table 5: Thermal cycling conditions for the Applied Biosystems® mitoSEQr™assay with Roche 
FastStart™ 
95°C 2 min  
95°C 30 sec 
35 cycles 60°C 30 sec 
72°C 45 sec 
72°C 7 min  
4°C hold  
 
2.2.3 PCR Purification and Cycle Sequencing 
  
 Quantification of the amplicons was performed with the Agilent Technologies® 
2100 Bioanalyzer® using the Agilent Technologies® DNA 1000 Kit™ (Agilent 
Technologies 2006a). Primers and unincorporated nucleotides were degraded by adding 2 
µl of USB® ExoSAP-IT® to 5 µl of the PCR reactions; this mixture was incubated 15 
min at 37°C followed by 15 min at 80°C (Affymetrix® 2011). The concentration of PCR 
product after USB® ExoSAP-IT® was recalculated, to account for the dilution 
introduced by the enzyme treatment. 
 Cycle sequencing was performed with Applied Biosystems® BigDye® Terminator 
v1.1 Ready Reaction Mix (Applied Biosystems® 2010), which was diluted in a 1:4 ratio 
with sterile water. In cases where the recalculated concentration of PCR product was 
 
 
38 
higher than 2.86 ng/µl, a half-volume reaction with diluted BigDye® reaction was 
performed, otherwise a full-volume reaction was performed (Table 6). 
Table 6: Cycle sequencing reaction conditions with diluted Applied Biosystems® BigDye® 
Terminator v1.1 Ready Reaction Mix 
 
Reagent Half-volume Reaction 
(>2.86 ng/µ l) 
Full-volume Reaction 
(<2.86 ng/µ l) 
BigDye, diluted 1:4 4.75 µl 9.5 µl 
M13 Primer (Forward or 
Reverse), 0.56 µM final 
concentration 
1.75 µl 3.5 µl 
Template 10 ng Up to 10 ng 
Sterile water 3.5 µl 7 µl 
 
 For the pGEM sequencing control, which is provided with the BigDye® kit, 3.5 µl 
of DNA (0.2 µg/µl) was used in half-volume reactions and 5 µl was used in full-volume 
reactions. Thermal cycling was performed as shown in Table 7 on an Applied 
Biosystems® Veriti® 96-Well thermal cycler. 
Table 7: Thermal cycling parameters for cycle sequencing with diluted Applied Biosystems® 
BigDye® Terminator v1.1 Ready Reaction Mix 
 
96°C for 1 min  
96°C for 10 s 
25 cycles 50°C for 5 s 
60°C for 4 min 
4°C hold  
 
2.2.4 Cycle Sequencing Purification and Capillary Electrophoresis 
 
 Purification of the cycle sequencing product was performed with Agencourt® 
CleanSeq® beads (Agencourt®). For half-volume reactions, 5 µl of reaction was purified 
using 10 µl of beads and 31 µl of 85% ethanol. For full-volume reactions, 10 µl of 
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reaction was purified using 10 µl of beads and 42 µl of 85% ethanol. The DNA was 
eluted in 40 µl of 0.1 mM EDTA and 30 µl was sequenced on the Applied Biosystems® 
3130xl Genetic Analyzer with POP-6™ polymer. Base calling was performed with 
Applied Biosystems® Sequencing Analysis 5.2 and Gene Codes Sequencher® 5.0 was 
used to identify variants from the rCRS. 
 
2.3 Mitochondrial DNA Quantification  
 
 The quantity of mtDNA in samples was assessed with the human mitochondrial 
DNA specific qPCR assay mentioned in chapter 1.4, as described by Kavlick et al 
(2011). 
 After distribution of the master mix and controls, wells of the optical plate were 
loosely capped with optical caps and covered with cross-linked aluminum foil to 
minimize photobleaching of the reagents. Then, the standard dilution series was created 
and pipetted in duplicate into its respective wells. Outer gloves were changed after each 
standard. When possible, samples were pipetted in triplicate and wells were capped, after 
which the plate was centrifuged to consolidate the reagents. Plates were run on an ABI 
PRISM® 7000 Sequence Detection System with Sequence Detection Software v. 1.2.3 or 
an Applied Biosystems® 7500 Real-Time PCR System with HID Real-Time PCR 
Analysis Software v. 2.0.1. 
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2.4 Long PCR Amplification of Buccal Swab Extracts 
 
 To amplify the entire mtGenome in two reactions, two novel primer sets were 
designed to overlap at the HV region, to potentially double sequence coverage in these 
regions (Table 8).  
 
Table 8: Long PCR primer sets. Set 1: 9,065 bp amplicon, Set 2: 11,170 bp amplicon. 
 
 1F 5’ AAA GCA CAT ACC AAG GCC AC 3’  
 1R 5’ TTG GCT CTC CTT GCA AAG TT 3’  
 
 2F 5’ TAT CCG CCA TCC CAT ACA TT 3’  
 2R 5’ AAT GTT GAG CCG TAG ATG CC 3’  
 
 These two primer sets were used to amplify approximately 200,000 copies of 
mtDNA as template in two separate reactions (Table 9) with the TaKaRa® LA Taq 
system described in section 1.3.1 (TaKaRa Bio Inc. 2013). 
 
Table 9: Reaction conditions for Long PCR with TaKaRa® LA Taq® 
 
Reagent µ l/reaction Final concentration 
DNA Template (200,000 copies 
mtDNA) 1 - 
Forward primer 1 0.2 µM 
Reverse primer 1 0.2 µM 
10x TaKaRa® LA PCR buffer 5 1x 
TaKaRa® LA dNTP mix (2.5 
mM each) 8 0.4 mM each 
TaKaRa® LA Taq® polymerase 
(5U/µl) 0.5 2.5U 
Sterile water 33.5 -- 
Total volume 50 - 
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 In addition, 1 ng of HL60 DNA was amplified as a positive control and 10 µl of 
sterile water was used as a negative control for both primer sets. Thermal cycling was 
performed as described in Table 10 on an Applied Biosystems® Veriti® 96-Well thermal 
cycler. Thermal cycling conditions were adapted from the vendor’s protocol to 
incorporate a separate annealing step and to extend the extension time to 11 minutes, as 
the vendor recommends an extension time of 1 minute per kb of target DNA. 
 
Table 10: Thermal cycling conditions for Long PCR with TaKaRa® LA Taq® 
94°C 1 min  
94°C 30 sec 
30 cycles 54°C 15 sec 
68°C 11 min 
72°C 10 min  
4°C hold  
 
 After amplification, the long PCR products were quantified using the Agilent 
Technologies® 2100 Bioanalyzer® using the Agilent Technologies® DNA 12000 Kit™ 
which is able to quantify DNA fragments of 100 - 12,000 bp in size (Agilent 
Technologies 2006b). Samples were purified with the Zymo® Clean & Concentrator-5™ 
kit using a 2:1 v/v ratio of DNA binding buffer to PCR product (Zymo Research) and 
requantified with the Agilent Technologies® DNA 12000 Kit™.  
 
2.5 National Institute of Standards and Technology Standards for Sequencing 
 
 The National Institute of Standards and Technology (NIST) provided two sets of 
sequencing standards: Standard Reference Material (SRM) 2392 and 2394. SRM 2392, 
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Mitochondrial DNA Sequencing Standard (Human), is comprised of DNA extracts of the 
highly characterized lymphoblastoid cell lines 9947A and CHR as well as the cloned 
HV1 region from CHR (Levin, Cheng, and Reeder 1999). SRM 2394, Heteroplasmic 
Mitochondrial DNA Mutation Detection Standard, is comprised of a 285 bp amplicon 
amplified from CHR and 9947A, which differ by a single base pair at the same nucleotide 
position. These two amplicons have been mixed at ten defined ratios ranging from 1 to a 
100% (Hancock, Tully, and Levin 2005). The SRMs were prepared for NGS alongside 
the LPCR amplicons as detailed in section 2.6. They were sequenced without any PCR 
amplification, to assess their value for use as sequencing controls. 
 
2.6 Illumina® Nextera® XT and Sequencing on Illumina® MiSeq™ 
 
 In total, 25 samples were processed with Illumina® Nextera® XT: long PCR 
products of eight donors, three reagent blanks for the corresponding DNA extractions and 
an HL60 positive control, as well as all three SRM 2392 standards and all ten SRM 2394 
standards which were not PCR amplified prior to sequencing.  
 The NIST standards were diluted to 200 pg/µl with sterile water, and 5 µl (1 ng) of 
each standard was pipetted into a separate well of a 96-well plate. For the LPCR samples, 
the 11.1 kb amplicons were diluted to 200 pg/µl and the 9.1 kb amplicons were diluted to 
162 pg/µl with sterile water, after which 2.5 µl of both were pooled into a well of the 96-
well plate, for a total of 0.905 ng which is slightly less than the recommended input. Due 
to the lower molecular weight of the 9.1 kb amplicon compared to the 11.1 kb amplicon, 
the 9.1 kb amplicons were diluted to a lower concentration than the recommended 200 
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pg/µl. This was performed in an attempt to equalize the number of 9.1 kb and 11.1 kb 
fragments for each donor, which may balance sequence coverage throughout the 
mtGenome. For each reagent blank, 2.5 µl of each PCR reaction (9.1 and 11.1 kb) was 
pooled undiluted into a separate well of the 96-well plate. 
 Tagmentation was performed on an Applied Biosystems® Veriti® 96-Well thermal 
cycler and followed by neutralization, after which each sample was assigned a unique 
index combination according to Illumina® guidelines (Illumina® 2012). Indexes and 
adapters were incorporated during a limited-cycle PCR amplification, which was 
performed on the Veriti® thermal cycler. Libraries were stored on the thermal cycler at 
10°C overnight.  
 Purification of the PCR product was performed with a 0.6x ratio of Agencourt® 
AMPure® XP beads to PCR product, which is recommended by Illumina® when starting 
with DNA larger than 500 bp. Purification was immediately followed by library 
normalization with Nextera® XT magnetic beads. The libraries were then quantified with 
the Qubit® ssDNA Assay kit. All normalized samples were pooled into the Pooled 
Amplicon Library (PAL).  
 Illumina® PhiX Control, derived from the highly characterized phiX174 (RF1) 
bacteriophage which has a 5386 bp circular genome (Thermo Scientific), is commonly 
used as an Illumina® sequencing control (Kircher, Stenzel, and Kelso 2009). A 12.5 pM 
concentration of Illumina® PhiX v3 Control was spiked into the PAL at a 20% v/v ratio 
(Illumina® 2013b) prior to the 25-fold dilution of the PAL to create the Diluted 
Amplicon Library (DAL). A sample sheet was set up in Illumina®’s Experiment 
Manager to sequence all 25 samples in a Resequencing workflow with Nextera® XT as 
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the library preparation method and the rCRS as reference genome. Each sample and its 
corresponding indices were listed in the sample sheet, and the Somatic Variant Caller was 
specified for variant calling with a frequency cutoff of 0.001. The sample sheet was then 
uploaded into the MiSeq™ Control Software, which guides the user through loading of 
the reagents and allows for visualization of quality statistics during the progress of the 
run.  
The DAL was sequenced on the Illumina® MiSeq™ in a 2x150 bp paired end v2 
run. Sequencing analysis was performed with Illumina® Sequence Analysis Viewer 1.8, 
Illumina® MiSeq™ Reporter 2.2 and Integrative Genomics Viewer 2.2 and 2.3. NGS 
sequences were compared to those derived for the same donors with Sanger sequencing 
(section 2.1). Positions that did not exhibit a common base in this comparison of 
treatments were designated as sequence differences. 
 
2.7 Whole Genome Amplification of Buccal Extracts 
 
 Initially, Whole Genome Amplification was performed on dilutions of buccal swab 
extracts, to determine if, and how well, WGA would amplify mtDNA in robust low copy 
number DNA samples.  
 DNA was extracted from buccal swabs as described previously in section 2.1. In a 
first experiment, DNA from one buccal swab extract was quantified and diluted serially 
to 100 pg/µl, 50 pg/µl, 25 pg/µl, 12.5 pg/µl, 6.25 pg/µl, 3.13 pg/µl, 1.56 pg/µl, 785 fg/µl, 
392.5 fg/µl and 196.25 fg/µl of nuclear DNA. In the second, extracts from two donors 
were serially diluted to 100 pg/µl, 3.13 pg/µl and 196.25 fg/µl nDNA. For the third 
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experiment, the same two extracts were serially diluted, but to a specific mtDNA copy 
number: 20250, 6750, 2250, 750 and 250 copies/µl.  
 In each experiment the dilutions, their reagent blank, a negative control and a 
positive control were processed with four different kits according to their manufacturer’s 
protocols, without any deviations. The QIAGEN® REPLI-g® Mini (QIAGEN® 2011a), 
Mitochondrial DNA (QIAGEN® 2011b) and the Sigma-Aldrich® GenomePlex® WGA2 
kit (Sigma-Aldrich® 2012) were used with 5 µl of DNA input. The QIAGEN® Single 
Cell (QIAGEN® 2012a) kit requires 2.5 µl input.  
 In the first experiment, 10 ng of QIAGEN® REPLI-g® Human Control DNA (10 
ng/µl) was used as a positive control. To preserve this positive control, in the second 
experiment 2.5 ng of the same control (diluted to 500 pg/µl) was used for the QIAGEN® 
REPLI-g® Mini kit and the Sigma-Aldrich® GenomePlex® WGA2 kit, but due to an 
oversight 1.25 ng was used for the REPLI-g® Mitochondrial DNA and Single Cell kits: 
the maximum input for the Single Cell kit (2.5 µl) was not taken into account. In the third 
experiment, 2.5 ng of the QIAGEN® control was used alongside 250 pg of an HL60 
control, the latter being a more forensically relevant concentration. 
 Amplification took place on an Applied Biosystems® Veriti® 96-Well thermal 
cycler as well as several Applied Biosystems® GeneAmp® PCR System 9700 thermal 
cyclers. A qPCR quantification of mtDNA in the WGA product was performed as 
described in section 2.3. Quantification of pre-WGA and post-WGA product for each kit 
was performed on the same 96-well optical plate to minimize variation between 
quantifications. With these data, the fold-increases of mtDNA after WGA were assessed. 
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2.8 Whole Genome Amplification of Hair Extracts 
 
 After experiments with buccal extracts, Whole Genome Amplification was 
performed on DNA extracted from hair shaft.  
 
2.8.1 Hair Shaft Extraction 
 
 One hair was obtained from each of three selected donors. DNA from these hairs 
was extracted following a newly developed hair extraction protocol (Burnside et al, 
2012). The hairs were observed under a Fisher Scientific™ Stereomaster™ microscope at 
25x magnification and the roots were removed. Two cm of hair nearest to the root was 
cut off and sonicated in 5% Alconox® Tergazyme™ for 20 minutes, after which the hair 
fragment was rinsed in 100% ethanol followed by a water rinse. The fragments were 
digested with QIAGEN® Buffer ATL, which was supplemented with proteinase K and 
dithiothreitol (DTT), at 56°C for one hour or until hairs were visibly digested. This 
digestion was followed by a brief incubation at 70°C with QIAGEN® Buffer AL 
(QIAGEN® 2010). The DNA was then purified using the Applied Biosystems® 
Prepfiler® Forensic DNA Extraction Kit (Applied Biosystems® 2012) and eluted in 50 - 
60 µl of Prepfiler® Elution Buffer. 
 
2.8.2 Whole Genome Amplification of Hair Shaft Extracts 
 
 Two duplicates of each hair extract, the reagent blank for the extraction process, a 
negative control and 2.5 µl of a 100 pg/µl HL60 positive control were amplified with the 
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QIAGEN® REPLI-g® Mini, Mitochondrial DNA and Single Cell kits as well as the 
Sigma-Aldrich® GenomePlex® WGA2 kit as described in section 2.7. However, since 
DNA from hair shaft extracts may already be fragmented, in two out of four cases the 
vendor’s protocol for the Sigma-Aldrich® GenomePlex® WGA2 kit was modified to 
omit the fragmentation step, in an attempt to improve DNA quality for downstream 
applications. According to vendor’s instructions, the fragmentation buffer was added, yet 
the fragmentation heating step was omitted. Again, qPCR quantification of mtDNA in 
pre- and post-WGA material was performed as described in section 2.3 on the same 96-
well optical plate to minimize variation between quantifications. 
 
2.8.3 Purification and Dilutions 
 
 WGA product from the QIAGEN® REPLI-g® Single Cell kit was suspected to 
cause unreliable qPCR quantification, as these samples resulted in high IPC values which 
indicated inhibition. On the other hand, the Sigma-Aldrich® GenomePlex® WGA2 kit 
showed lower IPC values than expected. Therefore, respectively 5 µl (eluted in 100 µl TE 
buffer) and 20 µl (eluted in 20 µl TE buffer) of product from these kits was purified using 
the Zymo® Clean & Concentrator-5™ kit (Zymo Research) as well as diluted 100-fold 
and 1000-fold with TE buffer prior to re-quantification with qPCR to test the efficiency 
of these methods in removing or diluting qPCR inhibitors.  
 In another purification experiment, Agencourt® AMPure® XP beads 
(Agencourt®) were used to purify the entire volume of WGA product from the 
QIAGEN® REPLI-g® Single Cell kit and the Sigma-Aldrich® GenomePlex® WGA2 
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kit. Subsequently, the Single Cell product was diluted 1000-fold and the GenomePlex® 
product was diluted 100-fold with sterile water. Then, both the AMPure® XP treated 
product and the diluted product were quantified with qPCR on the sample 96-well optical 
plate. The same purified product from the QIAGEN® REPLI-g® Single Cell kit was also 
diluted 100-fold with sterile water and quantified together with the 1000-fold dilution on 
the same 96-well optical plate with qPCR.  
 
2.9 Long PCR on Hair Shaft Extract and WGA Material 
 
 The optimized extraction protocol used in this study may allow for the 
amplification of longer fragments from hair shaft extracts. Thus, a hair from a single 
donor was extracted as described in section 2.8.1 and eluted in 60 µl of elution buffer. 
The hair extract was then quantified with qPCR as described in section 2.3. From this 
extract, 30 µl (approximately 180,000 copies of mtDNA) was used as DNA input in an 
attempt to amplify the 9.1 kb LPCR segment as described in section 2.4.  
 In addition, an effort was made to amplify the 9.1 kb LPCR segment of a single 
donor from WGA product of the QIAGEN® REPLI-g® Single Cell kit and the Sigma-
Aldrich® GenomePlex® WGA2 kit. This WGA product was purified with Agencourt® 
AMPure® XP beads as described in section 2.8.3. Again, LPCR conditions were 
followed as described in section 2.4, with mtDNA copy number input of 200,000, 
500,000 and 1,000,000 copies of purified WGA product. Likewise, 200,000 and 500,000 
copies of mtDNA of both post-WGA positive controls, as well as 10 µl of the post-WGA 
negative controls were amplified. The same copy numbers were targeted in an 
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amplification from WGA product that was purified and a thousand fold diluted with 
sterile water. 
 
2.10 Multiplex Amplification and Next Generation Sequencing of WGA Product from 
Hair 
 
 E. Burnside performed two multiplexed PCR amplifications with two four- or five-
plexes on the hair extracts and a subset of WGA product from each kit (Burnside et al, 
2013). Primers were adapted for NGS from published primer sequences of the Applied 
Biosystems® mitoSEQr™ kit, and amplify mtDNA amplicons of approximately 400 - 
700 bp in size. Table 11 shows the expected amplicon sizes for multiplex 1 (MP1) and 
multiplex 5 (MP5).  
 
Table 11: Expected amplicon sizes for multiplex 1 (MP1) and multiplex 5 (MP5).  
 
MP1 
Amplicon 
Sizes (bp) 
MP5 
Amplicon 
Sizes (bp) 
368 467 
636 609 
561 555 
599 597 
635  
 
 Amplification was performed with Roche FastStart™ master mix, reaction 
conditions as per Table 12. The same conditions were used for 1 ng of a 9947A positive 
control. 
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Table 12: Reaction conditions for multiplex PCR with Roche FastStart™ 
Reagent µ l/reaction Final concentration 
Roche FastStart™ High Fidelity Reaction 
Buffer 10x, with 18 mM MgCl2 
2.5 1x, 1.8 mM MgCl2 
DMSO 2.5 10 % 
dNTP Mix, 10 mM each 0.5 200 µM each 
Roche FastStart™ High Fidelity Enzyme 
Blend 0.25 1.25 U 
Primer mix 2.67 0.8 µM each 
Sterile water 14.58 - 
DNA template (various concentrations) 2 - 
Total volume 25 - 
 
 Amplification was performed as per Table 13 on an Applied Biosystems® Veriti® 
96-Well thermal cycler. 
 
Table 13: Thermal cycling conditions for multiplex PCR with Roche FastStart™ 
95°C 2 min  
95°C 30 sec 
36 cycles 55°C 30 sec 
72°C 1 min 
72°C 7 min  
4°C hold  
 
 In addition to performing the multiplex amplification, E. Burnside purified the PCR 
product with Agencourt® AMPure® XP beads, after which she quantified the resulting 
PCR product on the Agilent Technologies® 2100 Bioanalyzer® using the Agilent 
Technologies® DNA 1000 Kit™(Agilent Technologies 2006a). These quantifications 
were used in diluting the PCR product for NGS library preparation, by totaling the 
concentrations for each called peak and diluting this total concentration of DNA to 200 
pg/µl. 
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2.10.1 Purification and Qubit® Quantifications 
 
 To determine DNA input for Illumina® Nextera® XT, a subset of WGA product 
from the QIAGEN® REPLI-g® Single Cell kit and the Sigma-Aldrich® GenomePlex® 
WGA2 kit was quantified with the Invitrogen™ Qubit® 2.0 Fluorometer using the 
Qubit® dsDNA HS (invitrogen 2010) and ssDNA (invitrogen 2011) assay kits. The 
dsDNA HS kit quantifies double-stranded DNA, however, the ssDNA kit is not specific 
to single-stranded DNA (Life Technologies). Typically, 1 - 5 µl of WGA product was 
used as input for quantification.  
 Subsequently, these samples were purified with a 1.8x ratio of Agencourt® 
AMPure® XP beads to WGA product (Agencourt®) to retain only single-stranded and 
double-stranded DNA of 100 bp and higher, and quantified again using both Qubit® kits.  
 In an attempt to remove the excess of single-stranded DNA, which is not 
fragmented by Illumina® Nextera® XT (Illumina® 2012), the WGA product was treated 
with USB® Exo-SAP-IT® (Affymetrix® 2011) and requantified with the Qubit® using 
both kits.  
 Because the REPLI-g® Single Cell and Sigma-Aldrich® GenomePlex® samples 
were highly concentrated in mtDNA (many millions of copies) it was unknown whether 
these would generate many more clusters on the Illumina® MiSeq™ flow cell as 
compared to the other samples that would be run simultaneously. In addition, since the 
samples were excessively handled, there was a high chance of cross-contamination. 
Therefore, it was decided not to sequence this product on this MiSeq™ flow cell, and 
instead sequence only the REPLI-g® Mini and Mitochondrial DNA products. 
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2.10.2 Illumina® Nextera® XT and Sequencing on Illumina® MiSeq™ 
 
 Hair extracts processed with the REPLI-g® Mini and Mitochondrial DNA kits were 
quantified with the Invitrogen™ Qubit® 2.0 Fluorometer using the Qubit® dsDNA HS 
and ssDNA Assay kits to determine the total amount of dsDNA. WGA product was then 
diluted to 200 pg/µl of dsDNA based on these quantifications. In addition, the specific 
mtDNA copy number in these samples was quantified with qPCR. A second set of 
dilutions was based on molecular weight calculations based on these mtDNA 
quantifications.  
Both sets of WGA dilutions were prepared for sequencing, with a subset of the 
duplicates from some donors pooled together in an attempt to ameliorate possible 
amplification bias. Combined with these samples were the multiplex amplified product 
and a negative control for the Nextera® XT process, which accounted for a total of 53 
samples to be sequenced. These samples were each assigned a unique index combination 
and processed with Illumina® Nextera® XT as described before in section 2.6. All 
libraries were pooled with a 10% v/v spike-in of Illumina® PhiX Control v3 in the PAL. 
The PAL was then diluted 25-fold, to create the DAL. The DAL was sequenced on the 
Illumina® MiSeq™ in a 2x150 bp paired end v2 run. A sample sheet was designed and 
uploaded as described in section 2.6. Sequencing analysis was performed with Illumina® 
Sequence Analysis Viewer 1.8, Illumina® MiSeq™ Reporter 2.2, Integrative Genomics 
Viewer 2.3 and CLC bio® CLC Genomics Workbench 6.5. For the CLC Genomics 
Workbench analysis, parameters were as specified in Table 14.  
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Table 14: Analysis parameters for CLC bio® CLC Genomics Workbench 6.5. Default settings 
used unless otherwise specified in this table. 
 
Trim Sequences:  
• Quality trim 
• 5’ terminal nucleotides: 15 bases 
• 3’ terminal nucleotides: 10 bases 
• Remove short reads (15 bases or shorter) 
Map Reads to Reference:  
• Using unmasked NC_012920 
• Mismatch cost: 2 
• Insertion cost: 3 
• Deletion cost: 3 
• Ignore non-specific matches 
 Quality-based Variant Detection: 
• Minimum coverage: 100 
• Minimum Variant Frequency: 0.5% 
• Required & sufficient variant count: 10 
• Require presence in both forward and reverse reads 
• Ignore non-specific matches 
• Minimum neighborhood quality: 30 
• Minimum central quality: 30 
 
With these parameters, each read is trimmed at both ends and short reads are 
filtered out. The remaining reads are also trimmed for quality, according to an algorithm 
developed by CLC bio®, after which they are aligned to the reference sequence (CLC 
bio). This strategy allows for higher quality mapping, since primer sequences and low-
quality sequences are removed from the resulting data. For mapping, deletions and 
insertions are given a higher penalty than base mismatches, as few large gaps are 
expected in the mtGenome. If a read matches multiple regions of the reference, this read 
is ignored. For detection of variants from the rCRS, each position needs to be covered by 
a minimum number of 100 reads, and a variant needs to be detected in 10 reads or more 
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before it is called. In addition, the quality of the variant and the surrounding sequence 
should be Q30 or higher, and the variant should be seen in both forward and reverse 
reads. Again, non-specific matches are ignored. 
NGS data that were obtained for each WGA sample were compared to those 
derived from the LPCR samples on the MiSeq™ instrument for each donor (section 2.6). 
Positions that did not exhibit a common base in this comparison of treatments were 
designated as sequence differences. 
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CHAPTER 3: RESULTS 
 
 
3.1 Long PCR Amplification 
 
 Reference data for eight donors was successfully obtained with the Applied 
Biosystems® mitoSEQr™ kit as described in section 2.2. A list of variants from the rCRS 
from each donor are listed in Appendix I. 
 To generate mtDNA template from reference samples for NGS, DNA was extracted 
from buccal swabs from eight donors and the mtDNA copy number was quantified with 
qPCR. Approximately 200,000 copies (Table 15) were used as input for LPCR. An 
example of LPCR product is shown in Figure 14. 
 
  
Figure 14: Quantification of long PCR product. Performed with the Agilent Technologies® 2100 
Bioanalyzer® using the Agilent Technologies® DNA 12000 Kit™. Left: 11,170 bp amplicon. 
Right: 9,065 bp amplicon. Donor 002. 
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 The average PCR product generated for each donor was approximately 6.6 ng/µl 
(Table 15). LPCR amplification failed a number of times on DNA extracted from cotton 
buccal swabs that were dried and stored at room temperature. Subsequently, successful 
amplification was observed when performed on fresh buccal swabs taken from donors. In 
consequence, DNA extraction was performed in three different batches of 2 or 3 donors 
at a time, with a separate reagent blank used for each batch. None of these showed LPCR 
amplification.  
Table 15: Efficiency of long PCR amplification on buccal extracts. Average LPCR product is 
calculated as the average of the long and short amplicon per donor. A higher input for donor 003 
was used because 1 ng of nuclear DNA was targeted for this amplification. 
 
Donor 
Copies of mtDNA in 
Buccal Swab Extract 
LPCR Input 
(copies of mtDNA) 
Average LPCR 
Product (ng/µl) 
001  16,998,840,000 226000 5.35 
002  62,612,828 208709 6.78 
003  33,251,937 443359 10.52 
006  18,411,570,000 246000 7.23 
009  5,940,112,500 198000 5.30 
015  1,037,101,905 230467 8.66 
020  148,382,018 197843 7.34 
021  54,837,990,000 183000 5.42 
 
3.2 Long PCR Sequencing 
 
 After LPCR, the amplified product was processed with Illumina® Nextera® XT to 
generate sequencing libraries. Each amplicon was completely tagmented, into a broad 
peak of 100 - 400 bp visible on the Agilent Technologies® 2100 Bioanalyzer®. After 
normalization, a Qubit® quantification showed an average concentration of 250 pg/µl 
ssDNA for each sample. 
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 Libraries were sequenced on the Illumina® MiSeq™ using v2 kit reagents in a 
2x150 bp run. For this MiSeq™ run, 820K clusters/mm2 were detected. Since Illumina® 
guidelines recommend a cluster density of 50 - 1300K/mm2, with an optimum of 
800K/mm2, this run was accepted (Illumina® 2013a). In addition, 84.28% of the quality 
scores were Q30 or higher, and 90.19% of all clusters Passed Filter (PF), a quality-
filtering step.  
 All NGS data was analyzed with MiSeq™ Reporter (MSR) 2.2. Whole mtGenome 
data was obtained for each donor, as seen in Figure 15. The Sanger sequences (Appendix 
I) were compared to the NGS sequences (Appendix II) for each donor, and positions that 
did not exhibit a common base between the two compared sequences were designated as 
sequence differences. It should be kept in mind that due to the low resolution of Sanger 
sequencing, low-level mixtures or mixed positions may not be detected in the Sanger 
analysis. Therefore, some of the mixed positions detected in the comparison may be due 
to the distinctive levels in resolution obtained with the two methods.  
 It should be noted that bioinformatics software packages have known limitations 
with base calling in sequences that contain small insertions and deletions (indels). As the 
reads containing indels can independently be mapped to a reference sequence, this may 
result in multiple variant calls for a single indel (Albers et al. 2011). Therefore, 
misalignments and small indels in NGS data are omitted from the analysis results in this 
study.  
 In MSR, lower coverage is observed at the distal ends of the mtGenome. This may 
be due to the software’s inability to recognize the reference sequence as circular, which 
causes a lowering in coverage in these regions. 
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Figure 15: Whole mtGenome coverage graph from MiSeq™ Reporter for donor 002. Top: read 
coverage across the genome. Bottom: Quality scores. 
 
 The average whole mtGenome coverage of sequencing data for all donors was 
13072 reads in the MSR analysis (Table 16). The NGS data revealed 11 to 41 variants 
from the rCRS outside of the HV regions, with an average of 26. The median fragment 
length across all donors was 265 bp, which is consistent with the Agilent Technologies® 
2100 Bioanalyzer® size distributions of the Illumina® Nextera® XT libraries. 
 
Table 16: Variants from the rCRS, coverage and fragment lengths in whole mtGenome NGS data. 
Analysis performed with MSR. 
Donor Variants Outside of HV Regions 
Median 
Coverage 
Median Fragment 
Length (bp) 
001 23 6391 273 
002 28 13706.1 262 
003 27 13506.5 258 
006 11 17213.4 266 
009 12 16077.9 253 
015 41 15573.8 254 
020 31 12596.8 278 
021 36 9506.1 276 
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 In Table 17, an example of NGS data from one donor in this MiSeq™ run is shown. 
Data for the other donors can be found in Appendix II. 
 
Table 17: Variants from the rCRS in NGS and Sanger sequencing data from donor 002. Data was 
analyzed with MSR. Yellow: common base between Sanger and NGS analysis; Pink: low-level 
mixed position; Blue: low-level mixed position in homopolymer region.  
 
 
 NGS has enhanced capability to detect sequence mixtures. For example in donor 
001, an approximately 8% known low-level mixed position was detected at position 
16,093 (Appendix II). In the data set from donor 002 in Table 17, an “A” was observed at 
approximately 17% at position 15,673. Upon revisiting the Sanger sequence 
electropherograms for this donor, a mixed position was indeed present at 15.673 and the 
Sanger data was amended to include this finding (Figure 16). 
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Figure 16: Mixed base at position 15,673 in donor 002. This mixed position was noted in the 
Sanger sequence data after the NGS analysis. 
 
 Another category of low-level mixed positions was found in the MSR data, 
indicated in blue in Table 17. These occur around homopolymer regions (a contiguous 
occurrence of the same nucleotide). These mixed positions are not a result of primer 
binding mutations, which occur due to the incorporation of an amplification primer that 
contains base mismatches compared to the template but is still able to amplify this 
template. The observed mixed positions also do not cluster in specific reads, as would be 
seen with nuclear insertions of mitochondrial DNA (NUMTs) or arising from external 
contamination (Blanchard and Schmidt 1996). One particular deletion found at position 
12,417 (eight consecutive adenines) is seen at a frequency of approximately 4% in MSR 
data from all donors. Although this deletion was ignored in the analysis, it should be 
noted that it was also seen in MSR analyses of other MiSeq™ runs. These may be caused 
by a mixed position or could be an artifact of alignment as explained previously. Further 
evaluation of these deletions is warranted.  
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3.3 Sequencing of NIST Standards 
 
 The DNA sequencing standards described in section 2.5 that were obtained from 
the National Institute of Standards and Technology were sequenced to evaluate their use 
as sequencing controls. SRM 2392 consisted of three human DNA standards, which were 
two DNA extracts and a cloned HVI region, whereas SRM 2394 consisted of ten 
different mixtures of two amplicons with a single base mismatch at the same position. As 
the NIST standards were sequenced in the same MiSeq™ run as the long PCR amplicons, 
the same run statistics as stated in section 3.2 apply.  
 None of the NIST standards were PCR amplified prior to sequencing. In 
consequence, all three SRM 2392 standards show low coverage, although ssDNA 
quantification of the sample post-normalization did show ssDNA quantities similar to the 
LPCR samples. Approximately 40 reads (40x) were observed across the entire 
mtGenome for both extracts, however these also showed reads mapping to the nuclear 
genome. A median of 950x coverage was detected for the cloned section of HV1. 
Adequate read depth is important to reliably detect low-level mixtures. As a result, it was 
not possible to call all variants from the rCRS for these samples. 
 The SRM 2394 standards were analyzed with MSR. Depth of coverage across the 
amplicons varied. All showed high coverage, with an average depth of approximately 
412,000 reads at the position of the mixed base (Table 18). The median coverage across 
the entire amplicon was often higher, up to twice as high on one occasion. One of the 
samples was sequenced at a lower depth than the others, but it was possible to detect a 
low-level mixture. The reported frequency of bases was very close to the expected 
frequencies reported by NIST. 
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Table 18: Evaluation of NGS data accuracy from NIST Mixture Standards. Expected and called 
mixture frequencies of base position 6,317 in all ten standards. Data derived from MSR. 
 
Sample ID Base expected 
Freq. 
(%) 
Base 
called 
Freq. 
(%) Depth 
NISTMix1 T 100 T 99 274063 
NISTMix2 C 100 C 100 394144 
NISTMix3 T/C 50 T/C 52 468301 
NISTMix4 T/C 40 T/C 41 467779 
NISTMix5 T/C 30 T/C 31 566795 
NISTMix6 T/C 20 T/C 22 381094 
NISTMix7 T/C 10 T/C 11 480589 
NISTMix8 T/C 5 T/C 6 319786 
NISTMix9 T/C 2.5 T/C 4 39130 
NISTMix10 T/C 1.0 T/C 2 727996 
 
3.4 Whole Genome Amplification on Buccal Swabs 
 
 Whole Genome Amplification studies were initially performed on buccal swab 
extracts to assess the efficacy in augmenting mtDNA in a robust sample type. This was 
determined by the “fold increase” of mtDNA in the WGA material: the increase in 
mtDNA copy number as compared to the input. In the first experiment, a dilution series 
was based on nDNA quantification. WGA with all four kits mentioned in section 1.5.2 
was performed on these dilutions, prepared from the extracted DNA of one donor (Table 
19/Figure 17).  
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Table 19: First experiment: WGA performed on diluted buccal extract from a single donor. 
Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Lowest, average and highest fold 
increase calculated for all donor samples, controls excluded. Italics: copies not observed in all 
triplicate quantifications. 
Input Fold Increase 
nDNA *mtDNA copies/ul 
Q®R® 
Mitochondrial 
DNA 
Q®R® Mini 
S-A® 
GenomePlex® 
WGA2 
Q®R® 
Single Cell 
100 pg/µl 13,282 185 945 830 31,751 
50 pg/µl 7,441 82 1,262 853 30,089 
25 pg/µl 3,265 2,409 3,073 891 44,207 
12.5 pg/µl 1,758 155 2,984 892 77,338 
6.25 pg/µl 740 1,436 5,856 946 303,939 
3.13 pg/µl 380 3 8,300 1,024 339,893 
1.56 pg/µl 165 198 29,581 1,529 287,843 
785 fg/µl 79 746 20,108 785 1,163,055 
392.5 fg/µl 64 266 8,520 1,188 681,678 
196.25 fg/µl 31 16 466 1,021 7 
QIAGEN® Pos 2,647,627 5,499 87 1,839 621 
WGA Neg 0 0 0 0 0 
RB 0 5 0 41 5 
Lowest 3 466 785 7 
Average 550 8,109 996 295,980 
Highest 2,409 29,581 1,529 1,163,055 
*5 µl used for Sigma-Aldrich® GenomePlex® WGA2 Kit and QIAGEN® REPLI-g®, 
Mitochondrial DNA and Mini kits, 2.5 µl used for QIAGEN® REPLI-g® Single Cell kit 
Figure 17: First experiment: WGA performed on diluted buccal extract from a single donor. 
Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Box: lower and upper quartile limits. 
Whiskers: lowest and highest fold increases. 
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 It should be noted that these experiments with buccal swab extractions were 
performed before it was discovered that material in WGA product from the QIAGEN® 
REPLI-g® Single Cell kit interferes with the qPCR quantification (see section 3.6). 
Therefore, the reported values for the Single Cell kit may underestimate the actual 
mtDNA concentration in these samples. 
 In the second experiment, another dilution series different from the first experiment 
was prepared from the extracted DNA of two donors and WGA was performed on these 
dilutions (Table 20/Figure 18).  
 
Table 20: Second experiment: WGA performed on diluted buccal extracts from two donors. 
Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Lowest, average and highest fold 
increase calculated for all donor samples, controls excluded. Italics: copies not observed in all 
triplicate quantifications.  
Input Fold Increase 
*mtDNA 
copies/ul 
Fold Increase 
nDNA *mtDNA copies/ul 
S-A® 
GenomePlex® 
WGA2 
Q®R® 
Mini 
Trial 1 
Q®R® 
Mini 
Trial 2 
Q®R® 
Mitochondrial 
DNA 
Q®R® 
Single 
Cell 
002 100 pg/µl 24,696 395 27 105 44,007 180 30,596 
002 3.13 pg/µl 816 552 19 217 1,388 310 294,612 
002 196.25 fg/µl 51 1,003 85 5 86 22 228,322 
020 100 pg/µl 12,084 541 60 218 20,191 609 15,087 
020 3.13 pg/µl 379 581 59 293 510 17 222,015 
020 196.25 fg/µl 29 193 103 125 29 3 14,791 
RB 4 0 0 0 4 0 0 
QIAGEN® Pos 118,617 981 96 147 99,345 1,707 8,848 
WGA Neg 0 0 0 0 0 0 0 
Lowest 193 19 5   3 14,791 
Average 544 59 160   190 134,237 
Highest 1,003 103 293   609 294,612 
*5 µl used for Sigma-Aldrich® GenomePlex® WGA2 and QIAGEN® REPLI-g® Mini kits, 2.5 µl 
used for QIAGEN® REPLI-g® Single Cell and Mitochondrial DNA kits 
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Figure 18: Second experiment: WGA performed on diluted buccal extracts from two donors. 
Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Box: lower and upper quartile limits. 
Whiskers: lowest and highest fold increases. 
 
 
 In the third experiment, a dilution series was again prepared from the extracted 
DNA of two donors and WGA was performed on these dilutions, however this time the 
dilutions were based on a specific mtDNA copy number, not an nDNA concentration 
(Table 21/Figure 19-20).  
 
 
 
 
 
 
 
1 
10 
100 
1000 
10000 
100000 
1000000 
S-A® 
GenomePlex® 
WGA2 
Q®R® Mini 
Trial 1 
Q®R® Mini 
Trial 2 
Q®R® 
Mitochondrial 
DNA 
Q®R® Single 
Cell 
Fo
ld
 in
cr
ea
se
 
WGA on Buccal Swab Extracts - Experiment 2 
Mean 
Pos. Control 
 
 
66 
Table 21: Third experiment: WGA performed on diluted buccal extracts from two donors. 
Q®R®: QIAGEN® REPLI-g®. Lowest, average and highest fold increase calculated for all 
donor samples, controls excluded.  
Input Fold Increase 
Sample ID *mtDNA copies/µl 
Q®R® 
Mini 
Q®R® 
Mitochondrial 
DNA 
002 20250 565 27,598 
002 6750 1,013 12,348 
002 2250 1,157 26,029 
002 750 289 403 
002 250 11,971 44,278 
020 20250 863 7,789 
020 6750 1,135 24,679 
020 2250 2,169 4,288 
020 750 3,413 188,171 
020 250 4,748 14,847 
RB 0 0 0 
QIAGEN® Pos 69,560 256 4,949 
HL60 Pos 18,955 480 1,320,342 
WGA Neg 0 0 0 
Lowest 289 403 
Average 2,732 35,043 
Highest 11,971 188,171 
*Used 5 µl input for both kits 
 
Figure 19: Third experiment: bar chart of WGA performed on diluted buccal extracts from two 
donors. Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®.  
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Figure 20: Third experiment: box plot of WGA performed on diluted buccal extracts from two 
donors. Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Box: lower and upper quartile 
limits. Whiskers: lowest and highest fold increases. 
 
 It should be noted that these results are preliminary since limited data is available 
and there was a wide range of values obtained from many of the replicates. Fold increases 
from experiment to experiment were inconsistent for all kits except the Sigma-Aldrich® 
GenomePlex® WGA2 kit. Fold increases are not consistent with copy number input for 
any of the WGA kits. This inconsistency may be due to low DNA input into the WGA 
reactions: many WGA manuals recommend 1-10 ng of DNA template as input. 
Differences may also lie in pipetting accuracy: small changes in input may cause 
noticeable differences in fold increases. Lastly, differences may be due to chance. A few 
more primer binding events in the initial stages of the MDA process could facilitate a 
higher degree of amplification in total. 
 In these few preliminary experiments, it is evident that the QIAGEN® REPLI-g® 
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Single Cell kit resulted in a high fold increase in mtDNA copy number. The QIAGEN® 
REPLI-g® Mitochondrial DNA and Mini kits as well as the Sigma-Aldrich® 
GenomePlex® WGA2 kit showed lower fold increases. These results are concordant with 
previous studies, which show inconsistent fold increases in mtDNA in pristine samples 
with lower mtDNA concentrations (Maragh et al. 2008). 
 In the first experiment, the QIAGEN® REPLI-g® Mini kit showed a higher 
average fold increase than in the second or third experiment. Therefore, during the 
second experiment a second trial was done with new reagents, however the increases did 
not return to the levels seen in the first experiment. 
 
3.5 Whole Genome Amplification on Hair Shaft Extract 
 
 After experiments with buccal extracts, Whole Genome Amplification was 
performed on hair shaft extracts to assess the efficacy in augmenting the mtDNA copy 
number in challenging sample types. DNA from a single hair shaft was extracted from 
each of three donors. After each DNA extraction, WGA was performed in duplicate for 
each hair shaft extract, after which the increase in mtDNA copy number was assessed 
with qPCR. This experiment was replicated three times, using freshly extracted DNA 
from hair shafts each time (Tables 22, 23 and 24/Figure 21). 
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Table 22: WGA performed on hair shaft extract from three donors, first experiment. Q®R®: 
QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-
Aldrich®. Lowest, average and highest fold increase calculated for all donor samples, controls 
excluded. Italics: copies not observed in all triplicate quantifications. 
Input Fold Increase 
Sample ID mtDNA copies/µl 
Q®R® 
Mitochondrial 
DNA 
S-A® 
GenomePlex® 
WGA2 
Q®R® 
Mini 
002-1 28,462 2 429 3 
002-2 28,462 3 484 2 
009-1 7,942 2 422 2 
009-2 7,942 2 308 2 
020-1 19,834 3 627 12 
020-2 19,834 3 744 54 
HL60 Pos 78,967 233,801 921 745 
RB 0 0 20 0 
WGA Neg 0 0 33 7 
Lowest 2 308 2 
Average 2 502 13 
Highest 3 744 54 
 
 
Table 23: WGA performed on hair shaft extract from three donors, second experiment. Q®R®: 
QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. NF: No Fragmentation step. Lowest, average 
and highest fold increase calculated for all donor samples, controls excluded. Italics: copies not 
observed in all triplicate quantifications. 
Input Fold Increase 
Sample ID mtDNA copies/µl 
Q®R® 
Mini 
S-A® 
GenomePlex® 
WGA2 
Q®R® 
Mitochondrial 
DNA 
S-A® 
GenomePlex® 
WGA2 NF 
002-1 8,353 1 179 1 328 
002-2 8,353 1 176 1 - 
009-1 10,257 1 196 1 504 
009-2 10,257 1 340 1 - 
020-1 10,637 2 389 1 793 
020-2 10,637 1 476 2 - 
HL60 Pos 49,613 340 927 99,213 1,125 
RB 0 7 23 2 9 
WGA Neg 0 4,368 0 0 5 
Lowest 1 176 1 328 
Average 1 293 1 542 
Highest 2 476 2 793 
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Table 24: WGA performed on hair shaft extract from three donors, third experiment. Q®R®: 
QIAGEN® REPLI-g®. S-A®: Sigma-Aldrich®. NF: No Fragmentation step. Lowest, average 
and highest fold increase calculated for all donor samples, controls excluded.  
Input Fold increase 
Sample ID mtDNA copies/µl 
Q®R® Single 
Cell 
S-A® 
GenomePlex® 
WGA2 NF 
002-1 5,965 17,373 271 
002-2 5,965 144,679 360 
020-1 10,030 1,176 638 
020-2 10,030 109,052 884 
HL60 Pos 39925 31,745 823 
RB 0 0 0 
WGA Neg 0 0 0 
Lowest 5 0 
Average 45,384 359 
Highest 144,679 884 
 
 
Figure 21: All WGA experiments on hair shaft combined. Q®R®: QIAGEN® REPLI-g®. S-
A®: Sigma-Aldrich®. NF: No Fragmentation step. Number of replicates noted in parentheses 
behind method name. Box: lower and upper quartile limits. Whiskers: lowest and highest fold 
increases. 
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 Similar to the experiments with DNA from buccal swabs, WGA on hair shaft DNA 
extracts also results in inconsistent increases in mtDNA copy number for all kits except 
the Sigma-Aldrich® GenomePlex® WGA2 kit. In this study, the QIAGEN® REPLI-g® 
Single Cell kit shows higher fold increases in mtDNA copy number from hair shaft 
extracts than is exhibited by the QIAGEN® REPLI-g® Mitochondrial DNA and Mini 
kits and the Sigma-Aldrich® GenomePlex® WGA2 kit. Again, it should be noted that 
these results are preliminary, since a wide range of values was obtained from many of the 
replicates. 
 In the third batch of extractions, the hair shaft extract from donor 009 yielded very 
little mtDNA, most likely due to an error during extraction. This extract showed low fold 
increases after WGA with both kits, and is therefore excluded from these results. 
 
3.6 Purification of WGA Product 
 
3.6.1 Obtaining Accurate qPCR Quantification Values 
 
 The IPC assay used in qPCR quantifications is used to verify whether the reagents 
and the instrument are working properly and to detect the presence of PCR inhibitors. 
Usually, IPC values exhibit a mean CT of approximately 28 on the ABI PRISM® 7000 
Sequence Detection System and a CT of 25 on the Applied Biosystems® 7500 Real-Time 
PCR System. These CT values normally increase as the DNA concentration in samples or 
standards increases due to competition for reagents; elevation becomes noticeable at 
mtDNA copy numbers of 10,000 - 100,000 and up (Kavlick et al. 2011). Upon qPCR 
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quantification of mtDNA in the WGA product it was evident that for the QIAGEN® 
REPLI-g® Single Cell kit, Internal Positive Control (IPC) CT values were elevated in the 
WGA product (CT = undetermined for most samples on both the 7000 and 7500 
instrument). However, the IPC CTs for the Single Cell kit were also elevated in the post-
WGA negative controls, which did not contain any mtDNA. Although Single Cell 
samples from hair shaft contained millions of copies of mtDNA, which could affect the 
assay as mentioned before, the negative control indicated that reagents in the Single Cell 
kit also attributed to elevated qPCR IPC CT values. The effects of WGA kits on qPCR 
need to be better understood in order to obtain accurate qPCR quantification results. 
 A similar occurrence was seen with the Sigma-Aldrich® GenomePlex® WGA2 kit, 
yet IPC values were often at the same level or lower than the negative controls (CT = 24 
for the 7500 instrument, and 28 for the 7000) even though changes in IPC CT values 
should have been observed as these samples contained high concentrations of mtDNA. 
This indicated that reagents from the GenomePlex® kit were possibly influencing the 
qPCR assay as well.  
 In an effort to further study the qPCR effects in these samples, a subset of samples 
from both kits were purified with Agencourt® AMPure® XP magnetic beads or the 
Zymo® Clean & Concentrator-5™ column purification kit. Upon requantification, IPC 
values did change, however this was consistent with the high mtDNA concentrations in 
these samples, which can elevate IPC values due to reagent depletion as mentioned 
previously. After diluting the products of both kits (in some cases purified, in some cases 
not) a 100-fold and 1000-fold with sterile water, results did no longer indicate the 
presence of inhibitors.  
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 It should be noted there was no change between mtDNA copy number results for 
the GenomePlex® samples before or after purification/dilution. However, these 
treatments were necessary to facilitate successful PCR amplification in these samples 
(section 3.7). The Single Cell kit results after purification/dilution showed that these 
samples contained more mtDNA copies than was initially quantified. These results 
suggest that WGA product arising from the use of these kits may require purification and 
dilution prior to the downstream applications. 
 As stated previously, the inhibitory effect in Single Cell kit reagents was not 
detected during the WGA experiments with buccal swab extracts. Therefore, fold 
increases in mtDNA for samples from the Single Cell kit may be underestimated in these 
experiments.  
 
3.6.2 DNA Purification Prior to Library Preparation 
 
 To determine the optimal DNA input for Illumina® Nextera® XT processing, 
single-stranded and double-stranded DNA (ssDNA and dsDNA) were quantified with the 
Qubit® 2.0 using both the ssDNA and dsDNA quantification kits. The ssDNA 
quantification was performed because ssDNA is not a substrate for Illumina® Nextera® 
XT, and it was unknown whether excess amounts of ssDNA would interfere with the 
library preparation method. It should be noted that the dsDNA kit quantifies dsDNA 
specifically, yet the ssDNA kit quantifies both ssDNA as well as dsDNA and RNA in a 
sample (Life Technologies). Therefore, both dsDNA and ssDNA quantifications need to 
be performed and the quantification value for dsDNA should be subtracted from the 
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ssDNA quantification value if the ssDNA concentration is sought. In addition, both kits 
are susceptible to varying degrees of signal change due to contaminants such as salts and 
organic solvents. 
 To determine the total dsDNA and ssDNA content of WGA products, an aliquot of 
product from the QIAGEN® REPLI-g® Single Cell kit and the Sigma-Aldrich® 
GenomePlex® WGA2 kit were quantified with both Qubit® kits. Both sample types 
initially showed a high ratio of ssDNA to dsDNA. Samples were purified with 
Agencourt® AMPure® XP beads and requantified. This resulted in a higher 
concentration of dsDNA in Single Cell kit product than was reported previously, which 
indicates that components in this kit or the WGA product influence the Qubit® 
quantification. However, the concentration of dsDNA and ssDNA in the GenomePlex® 
product was lowered after purification, which is consistent with the removal of primers 
and primer complexes by the magnetic beads. 
 Since ssDNA is not a substrate for Illumina® Nextera® XT, an attempt was made 
to remove ssDNA from the bead-purified WGA product using USB® ExoSAP-IT®, after 
which the product was requantified. High amounts of ssDNA were present in the Single 
Cell product, which was not completely removed after two purification steps with USB® 
ExoSAP-IT®, as assessed by Qubit® quantification. 
 
3.7 Multiplex Amplification of Hair Shaft Extract and WGA Material 
 
 Two different multiplex PCRs, each containing 4 or 5 different primer sets that 
target different portions of the mtGenome, were performed on a subset of hair shaft 
 
 
75 
extracts and WGA product from all four kits. Multiplex amplification was successful on 
unpurified WGA product of the QIAGEN® REPLI-g® Mitochondrial DNA kit (Figure 
22) and Mini kit (data not shown). Due to the low mtDNA augmentation in these samples 
it cannot be confirmed whether it was WGA product that was PCR amplified or whether 
or not this signal originated from PCR amplification of the initial DNA extract. However, 
these results do indicate that the Mini and Mitochondrial DNA kits likely do not contain 
reagents that are inhibitory to multiplex PCR amplification. 
Hair shaft extract, donor 002 
Mitochondrial DNA kit, donor 002
 
Figure 22: Multiplex PCR performed 
on hair extract and WGA material of 
donor 002. Material from the first 
hair shaft experiment, amplified with 
MP5 primers.  
 
Top: donor 002 extract, 26,554 
copies of mtDNA input. Total 
concentration of PCR product 24.06 
ng/µl.  
 
Bottom: corresponding WGA 
product from the QIAGEN® REPLI-
g® Mitochondrial DNA kit, 4,182 
copies input. Total concentration of 
PCR product 12.39 ng/µl.  
 
 No multiplex PCR amplification was obtained with unpurified WGA product from 
the GenomePlex® kit, using inputs of 90,000 to a 263,000 copies of mtDNA. Upon 
purification of the WGA product with the Zymo® Clean & Concentrator-5™ kit or a 
100-fold to a 1000-dilution with sterile water, amplification was successful and generated 
sufficient product for NGS library preparation (Figure 23). This same pattern was 
observed for the Single Cell kit (data not shown).  
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 In a 1000-fold diluted WGA sample only limited quantities of mtDNA from the 
original hair shaft extract remain. Therefore, in some cases the WGA product itself may 
be the supporting template for the observed successful multiplexed PCR amplification. 
However, these hair shaft extracts should have been diluted 1000-fold prior to multiplex 
amplification and sequencing, to determine whether or not the diluted extracts could 
support multiplexed PCR amplification at such a dilution factor. Thus, further studies are 
required to confirm these findings. 
A 
Zymo®  Purification
 
Figure 23: Multiplex PCR is 
successful after purifying or 
diluting WGA product. 
Product from Sigma-Aldrich® 
GenomePlex® WGA2 kit, 
donor 020. Material from the 
second hair shaft experiment, 
amplified with MP5 primers.  
  
A: WGA product purified with 
Zymo® Clean & Concentrator-
5™ kit. Total concentration of 
PCR product 25.41 ng/µl. 
 
B: WGA product diluted 100-
fold. Total concentration of 
PCR product 13.32 ng/µl. 
 
C: WGA product diluted 1000-
fold. Total concentration of 
PCR product 5.56 ng/µl. 
 
B 
Dilution, 100-fold
 
C 
Dilution, 1000-fold 
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3.8 LPCR on Hair Shaft Extract and WGA Material  
 
 An attempt to amplify the 9.1 kb LPCR fragment from a hair extract was not 
successful with 180,000 copies of mtDNA input (30 µl input). Whole Genome 
Amplification was performed with both the QIAGEN® REPLI-g® Single Cell kit, as 
well as the Sigma-Aldrich® GenomePlex WGA2 kit (fragmentation step omitted). 
Amplification of the 9.1 kb LPCR segment was only successful on an HL60 positive 
control that was amplified with the Single Cell kit and diluted to 200,000 and 500,000 
copies of mtDNA input. These samples resulted in 1.39 ng/µl and 13.17 ng/µl of LPCR 
product, respectively, although non-specific amplification of smaller fragments was 
observed. LPCR amplification was minimally successful (0.35 ng/µl) with 500,000 
copies of mtDNA from the same HL60 positive control used as input for the 
GenomePlex® kit. None of the WGA product from hair shaft extracts was successfully 
amplified with LPCR. 
 It should be noted that using 200,000 copies of mtDNA from a pristine positive 
control as input, product from both WGA kits yielded LPCR fragments at a concentration 
that was lower than usually observed at this level of input (approximately 5 - 10 ng/µl). 
These results indicate that these WGA methods likely shorten the DNA template during 
the amplification reaction. As mentioned in section 1.5.2, it is unlikely for MDA random 
hexamer primers to consistently anneal at the distal ends of a fragment. Thus, if a 
hexamer e.g. anneals in the middle of a fragment, only half of that fragment is amplified. 
This causes shortening of the DNA template. The GenomePlex® method incorporates a 
fragmentation step, and although this step may be omitted (section 2.8.2), it is possible 
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that the subsequent PCR amplification steps are not designed for amplification of longer, 
non-fragmented, template DNA strands. 
 
3.9 Sequencing of Putative WGA Product from Hair Shaft Extracts 
 
 In an attempt to determine the accuracy of WGA methods, a subset of WGA 
product and multiplex PCR product from this WGA product were sequenced. However, 
there is no direct evidence that the resulting sequence data originates from the WGA 
product itself, since the proper controls were not run. The following sample types were 
sequenced: 
1. WGA product from QIAGEN® REPLI-g® Mitochondrial DNA and Mini kit, no 
mtDNA-specific PCR amplification 
2. WGA product from all four kits, multiplex amplified with both multiplexes 
3. Extracts from all donors, no WGA, multiplex amplified with both multiplexes 
A total of 53 samples were sequenced in this Illumina® MiSeq™ run, the quality metrics 
were as follows:  
• 1046K clusters/mm2 (higher than the recommended 800K but still acceptable)  
• 91.5% of reads > Q30  
• 87.71% of clusters passed filter (PF) 
 
3.9.1 Whole Genome Amplified DNA Samples from Hair Shaft 
 
 WGA product from the QIAGEN® REPLI-g® Mitochondrial DNA and Mini kit 
that was not further PCR amplified was quantified and diluted according to two dilution 
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strategies. The first strategy was based on the mtDNA specific qPCR quantification 
values. In most cases, this resulted in no additional dilution prior to library preparation, 
except for the positive control of the Mitochondrial DNA kit. The second strategy was 
based on the Qubit® dsDNA quantifications: in these cases, the WGA product was 
diluted to 1 ng of dsDNA in each sample prior to library preparation.  
 Both dilution strategies of WGA product showed low NGS read coverage when 
mapped to the mtGenome. An average of 247,000 clusters were associated with these 
samples, and only a small percentage (0.004 - 2.029%) of clusters aligned to the 
mtGenome. This result was not unexpected, due to the differences in quantification 
values for the mtDNA-specific qPCR, and the non-specific Qubit® quantifications, 
combined with the fact that these samples were not further PCR amplified. 
 Although diluting the WGA product to 1 ng of dsDNA increases the number of 
clusters passing filter for almost all of these samples, it does not increase the percentage 
of clusters that align to the rCRS. An exception was the HL60 positive control for the 
Mitochondrial DNA kit, which showed an average coverage of approximately 1,000 
reads in the qPCR dilution and 4,000 reads in the Qubit® dilution. Approximately 38 - 
45% of the clusters associated with these samples aligned to the mtGenome. These data 
were compared to the sequences obtained with LPCR amplification and MiSeq™ 
sequencing (Appendix II). Some sequence differences were noted. These are positions 
that do not share a common base between two treatments, in this case WGA versus LPCR 
amplification of the same donor. The qPCR dilution showed one mixed position of 2.18% 
and the Qubit® dilution showed three mixed positions at frequencies between 1.22 and 
1.57%. However, as stated previously, there is no evidence that these sequence data can 
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be contributed to the WGA process. 
 Potentially, these two WGA kits create primer hyperbranches in cases of 
insufficient DNA input into the WGA reaction, as explained in section 1.5.2. This non-
specific product may then be tagmented by the library preparation and subsequently 
bridge amplified and sequenced by the NGS system, but does not generate mtDNA 
sequence data. This interpretation is supported by the observation that negative controls 
result in on average 1800 clusters with 0.27 - 3.55% of clusters aligning to the 
mtGenome, and the reagent blanks generate an average of 180,000 clusters with 0.01 - 
0.61% of clusters aligning.  
 A sterile water sample was used as input for the Illumina® Nextera® XT library 
preparation method. Naturally, no clusters are expected for this sample. However, 1360 
clusters passed filter for this sample, of which 7.6% aligned to the mtGenome, with a 
maximum read depth of 33. The majority of these reads align to areas targeted by the 
multiplex PCR primers. Considering 16 multiplex amplified samples were processed on 
the same 96-well plate with Nextera® XT, this indicates that the library preparation 
method may be sensitive to contamination if not handled with extreme care. 
 
3.9.2 Multiplexed Whole Genome Amplified Samples 
 
 In contrast to the unamplified samples described above, high-coverage NGS data 
was generated for the multiplex amplified samples, with an average of 441,000 clusters 
passing filter, of which approximately 93% mapped back to the rCRS. The median 
coverage across the mtGenome was 7,151 reads for these samples, since median coverage 
 
 
81 
is calculated as the total number of reads over the entire mtGenome. However, coverage 
was up to 250,000 - 300,000 reads in regions covered by the multiplexes (Figure 24). 
 
Figure 24: Coverage graph of WGA product amplified with multiplex PCR. HL60 processed with 
the Sigma-Aldrich® GenomePlex® WGA2 kit, diluted 1000x and amplified with MP5 primers. 
Trace derived from Illumina® MiSeq™ Reporter. 
 
 The accuracy of the sequence data derived from these multiplexed samples was 
determined by analysis in CGW (Table 25). Sequence differences arising from a 
comparison with LPCR data were noted as described in section 3.9.1. The PhiX 
sequencing control showed the expected sequence data. Thus, the direct comparison of 
NGS data from WGA material to LPCR product allowed for the observation of 
potentially WGA-induced effects on the DNA sequences. However, it cannot be excluded 
that differences arise from base misincorporations introduced by the tagmentation or PCR 
amplification steps in the library preparation method, and therefore differences cannot 
confidently be attributed to the WGA process.   
 Any sequence data obtained inside the multiplex primer binding regions or outside 
of the amplicon regions was discarded. Indel misalignments and small indels were not 
further analyzed. In addition, any low-level mixed positions below 1.0% were excluded 
from analysis, as it is yet unknown whether low-level mixtures below this threshold can 
be confidently called. 
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Table 25: Sequence differences in multiplex PCR data from WGA results. The NGS sequences 
from multiplexed WGA product were compared to the NGS sequences from LPCR product from 
the same donors, and differences or mixed positions between the corresponding mtDNA 
sequences were noted. Data derived from CGW. Q®R®: QIAGEN® REPLI-g®. S-A®: Sigma-
Aldrich®. MP: multiplex primer set used for amplification. Zymo: purified with Zymo® Clean & 
Concentrator-5™ kit. Dil: diluted. 
Template Donor MP Total # positions 
Highest 
frequency (%) Notes 
Hair shaft 
extract 
002 5 0 0 - 
009 5 17 2.02 - 
020 5 0 0 - 
020 1 2 5.44 Possibly biological? 
Q®R® 
Mitochondrial 
DNA kit 
002-2 5 3 1.5 - 
020-2 5 6 1.61 - 
Q®R® Mini 
kit 
020-2 1 6 30.7 Contaminated? 
HL60  1 21 14.46 - 
Q®R® Single 
Cell kit 
020-1 Zymo 1 18 13 - 
020-1 100x Dil 1 18 49.69 - 
020-1 1000x Dil 1 17 52.87 - 
HL60 1000x Dil 1 15 9.16 - 
S-A® 
GenomePlex® 
WGA2 kit 
020 Zymo 5 44 5.85 - 
020 100x Dil 5 76 8.56 - 
020 1000x Dil 5 36 21.79 - 
HL60 1000x Dil 5 50 3.2 - 
 
 One of the Mini kit samples (020-2, MP1) may have been contaminated since the 
negative control from this WGA reaction showed many mtDNA copies upon qPCR 
quantification. In addition, multiple mixed positions are called at positions of known 
variation from the rCRS for this donor, which is consistent with a DNA mixture of more 
than one donor. 
 The hair shaft extract from donor 020, amplified with multiplex 1 primers, shows a 
mixed position at a frequency of 5.44%, which is below the detection threshold of 10% 
for Sanger sequencing. This likely did not occur due to base misincorporations as a result 
of the incorporation of an amplification primer that contains mismatches compared to the 
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template, but is still able to amplify this template. Nor did other low-level mixed 
positions accompany this position, as would be the case with contamination. MtDNA 
sequences have been shown to fluctuate throughout tissue types in an individual (Wilson 
et al. 1997). Since this particular hair extract was sequenced only once, it is possible that 
the observed 5.44% mixed position is of biological nature. However, this cannot be 
confirmed until further sequencing is performed. 
 It should be noted that the 100-fold and 1000-fold dilutions of Single Cell kit 
product derived from hair shaft extracts show mixed positions at higher percentages than 
is exhibited by neat or diluted product from the other three kits. In contrast, the 
GenomePlex® kit shows a higher number of mixed positions than any of the other three 
kits. However, as stated previously, there is no evidence that WGA material is 
responsible for any of these NGS results. Since the proper controls were not run, the 
possibility remains that the extracted hair shaft DNA provided the DNA template for 
these multiplex PCR amplifications. 
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CHAPTER 4: DISCUSSION 
 
 
4.1 Sequence Comparison of Next Generation Sequencing vs. Sanger 
 
 In some instances in forensic casework nDNA may not be present in sufficient 
quantity or quality for STR analysis. In these cases, mtDNA is an excellent alternative. 
However, it is often too labor-intensive or expensive to sequence the entire mtGenome 
with traditional Sanger sequencing methods, and therefore analysis is frequently limited 
to the hypervariable regions. NGS allows for more cost-effective analysis of entire 
mtGenomes by obtaining more data points from the same sample. Here, a method is 
presented for the NGS analysis of entire mtGenomes from reference samples.  
 A long PCR approach successfully amplified the entire mitochondrial genome from 
buccal swabs from all eight donors. A single buccal swab generated ample amounts of 
DNA for LPCR processing: by using 200,000 copies of mtDNA from an extract as input, 
an average of 6 ng/µl of LPCR product was generated - Illumina® Nextera® XT requires 
only 1 ng of input.  
 However, since LPCR failed to amplify with DNA from cotton buccal swabs that 
had been stored at room temperature, but amplified well with fresh buccal swabs, it is 
possible that ongoing microbial activity allowed DNA degradation to occur. Thus, DNA 
extraction should be performed on buccal swabs that were freshly taken from the donor 
or stored on swabs with internal antimicrobial activity. Alternatively, extraction could be 
performed on cells that have been sloughed off from buccal swabs onto FTA cards, 
which exhibit antimicrobial activity and can be stored at room temperature for extended 
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periods of time (Whatman). 
 When compared to Sanger sequencing data, NGS data derived from long PCR 
amplicons generates the expected sequence. This includes known low-level mixed 
positions, for instance an 8% C to T transition in donor 001 at position 16,093, which is a 
known high mutation rate site (Tully et al. 2000)(Appendix I/II).  
 NGS data derived from the LPCR product span the entire mitochondrial genome at 
high coverage. The average coverage for all donor sequences was approximately 13,000x 
across the mtGenome. Due to the overlapping nature of the PCR primer sets, double 
sequence coverage was expected for the areas between nucleotides 15195 - 1892, which 
includes the non-coding region, as well as for 9397 - 9777. Elevated coverage was indeed 
seen in these regions, although coverage may be artificially lowered when using a non-
circularized genome for mapping. An increase in coverage in these regions facilitates 
even deeper observation of low-level mixtures. 
 It should be noted that indels currently present a limitation in NGS analysis, as read 
mapping algorithms are known to misalign reads containing these indels. Mapping 
algorithms will likely be improved in the near future. Although small indels were ignored 
in analyses in this study, it was noted that a low-level mixed base at position 12,417, 
which is located in a region with eight adenines, is seen consistently at a frequency of 
approximately 4% in the NGS data from all donors, and across different runs. This may 
indicate that this homopolymer is causing a sequencing issue with the Illumina® 
MiSeq™ instrument or an alignment issue with these software packages. Although 
homopolymer regions are known to be heteroplasmic (Bendall and Sykes 1995), more 
research is needed to determine the origin of this mixed position. 
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 As expected, the resolution with NGS is significantly higher compared to Sanger 
sequencing. Low-level sequence variation that had gone undetected in Sanger data was 
easily observed in the NGS data. In conclusion, the LPCR method is robust, easy to 
perform, and generates high coverage and high quality sequencing data. This makes it an 
excellent tool for generating whole mtGenome NGS sequence data from robust reference 
samples such as buccal swabs. 
 
4.2 Evaluation of Illumina® Nextera® XT Library Preparation for Forensic Casework 
 
Previously, library preparation presented one of the main bottlenecks in NGS 
analysis. Here, Illumina® Nextera® XT has shown to be an effective and rapid way of 
preparing libraries from different sources of DNA material for sequencing on the 
Illumina® MiSeq™ instrument, as libraries can prepared more quickly than with 
traditional library preparation methods. By incorporating indices, many samples can be 
run on the same flow cell, depending on the number of total indices available. The 
resulting sequence data can be demultiplexed, meaning that it is separated by its index 
reads and placed into distinct bins for each sample. The reported sequence data for each 
sample was as expected - exceptions to this are thought to arise mainly due to alignment 
issues. 
As a measure of contamination in the WGA sequencing run a sterile water sample 
was prepared for sequencing alongside the WGA product and multiplex PCR products, 
and received a separate index. Since contamination is a concern that is always present in 
forensic casework, and even more so in instances where mtDNA is the focus of analysis, 
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this may be an appropriate control for the detection of contamination in an NGS run, 
which is extremely sensitive to contamination due to the high clonal amplification and 
deep sequencing that is implemented in NGS. 
Upon sequencing, this control showed distinct contamination with multiplex PCR 
product, although three lanes on a 96-well plate separated the two sample types. This 
indicates that the control was contaminated with PCR product during the initial steps for 
tagmentation. This signal was likely increased during the suppression PCR in the 
Illumina® Nextera® XT protocol, as well as during bridge amplification during 
sequencing.  
The coverage level of contamination that was seen in this control was as high as 
35 reads in some areas of the mtGenome. As high-coverage data will likely be a 
requirement in forensic casework this level of contamination may be negligible. 
However, it may present a very real concern in low-coverage runs, and could influence 
data interpretation. Care should be taken with this library preparation method as to not 
cross-contaminate any materials that will be sequenced in the same run. 
 
4.3 Evaluation of NIST Standards as Sequencing Controls 
 
 Two sets of NIST standards were sequenced without any prior amplification to 
evaluate their utility as controls to assess sequencing quality on a run-to-run basis. SRM 
2392 is comprised of DNA extracts of the cell lines 9947A and CHR as well as the 
cloned HV1 region from CHR (Levin, Cheng, and Reeder 1999). SRM 2394 is comprised 
of two 285 bp amplicon amplified from CHR and 9947A, which differ by a single base 
pair at the same nucleotide position, and have been mixed at ten defined ratios ranging 
 
 
88 
from 1 to a 100% (Hancock, Tully, and Levin 2005). 
 The three SRM 2392 standards need to be amplified with mtDNA specific primers 
prior to sequencing. The extracts showed low coverage; nuclear DNA was present in 
these samples, which was also tagmented and sequenced. This resulted in a lower number 
of clusters mapping to mtDNA. The cloned HV1 region showed a similar problem: since 
the entire vector was sequenced, only a small portion of reads mapped back to the 
mtGenome. If these standards are to be used in the future, it is recommended that all 
samples be amplified before sequencing, whether with long PCR for the extracts, or 
HV1-specific primers for the cloned HV1 region. This will increase coverage, and thus 
increase resolution for these samples.  
 The SRM 2394 standards showed high sequence coverage for all mixtures. In 
addition, the observed frequencies were consistent with the expected frequencies reported 
by NIST. This indicates that these mixture standards may be implemented in future 
Illumina® MiSeq™ runs, to function as a sequencing control. 
 
4.4 Whole Genome Amplification 
 
 Although mtDNA in reference samples is often robust, this may not be the case for 
challenging sample types such as hair shafts. Template mtDNA in these samples may be 
degraded, which does not support amplification with long PCR prior to NGS. Therefore, 
a different preparation of mtDNA in these samples may be necessary to obtain whole 
mtGenome NGS data. Here, mtDNA was pre-amplified with four different Whole 
Genome Amplification kits. The resulting product, as well as PCR product from a 
multiplex PCR amplification, was analyzed with NGS. The following conclusions are 
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based on limited data, and should therefore be considered as preliminary. Additional 
work needs to be performed in order to confirm these findings.  
 In these experiments, the evaluated WGA kits amplify mtDNA from hair extracts 
less efficiently than from buccal swabs, with the exception of the PCR-based Sigma-
Aldrich® GenomePlex® WGA2 kit. Hair shaft extracts may contain degraded DNA, 
which has been stated to possibly decrease DNA yield in MDA reactions (Lage et al. 
2003). As with buccal extracts, all kits except the GenomePlex® kit were inconsistent in 
amplification when comparing replicate samples from the same hair shaft extract, as well 
as replicate experiments using different extracts.   
 Hair shaft DNA extracts processed with the QIAGEN® REPLI-g® Mini and 
Mitochondrial DNA kits showed low sequence coverage upon sequencing with the 
Illumina® MiSeq™, however, due to the low mtDNA concentrations in these samples, 
these were not expected to generate high-coverage data. In contrast, a positive control 
prepared with the Mitochondrial DNA kit resulted in high coverage throughout the entire 
mtGenome. These results indicate that WGA product of these two kits, using hair shaft 
extracts as DNA template, cannot directly be sequenced with the two dilution strategies 
that were used for library preparation. Further studies need to be performed to optimize 
the input of WGA product into the NGS library preparation method.  
 These samples from the Mini and Mitochondrial DNA kit were relatively low in 
mtDNA concentration, yet the quantification of total dsDNA and ssDNA was 
significantly higher. It is possible that the random hexamers in these kits branch off each 
other due to low input in WGA, which contributes to the total dsDNA concentration in 
the sample (Lage et al. 2003). This could explain why only a small percentage of clusters 
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that have been assigned to each index actually align to the mtGenome. Potentially, a 
molecular crowding agent can be used to amplify these sample types more efficiently 
(Ballantyne et al. 2006). 
 Another solution for the low coverage in these samples could be evaluated by 
performing purification steps prior to sequencing. It is possible that by purifying these 
samples, primers and other reagents in the WGA product could be removed. In addition, 
the DNA template may be concentrated in a smaller volume. As such, the input of 
mtDNA into Illumina® Nextera® XT may be increased.  
 Amplification bias may be a concern with WGA techniques. Although pooling 
strategies were attempted to ameliorate the effects of possible unequal amplification, the 
coverage in these samples was too low to conclude whether any such amplification bias 
was present in these samples or whether the pooling strategy was an appropriate method 
of reducing bias.  
It should be noted that due to their higher mtDNA concentrations, material from 
the Sigma-Aldrich® GenomePlex® WGA2 kit and the QIAGEN® REPLI-g® Single 
Cell kit may generate sequence data of a sufficient coverage for low-level mixture 
detection. However, material from these kits was not sequenced, due to concerns about 
their concentration with respect to other samples on the flow cell, as well as the 
possibility of cross-contamination due to frequent handling of these samples.  
Long PCR amplification on hair extracts is not possible, as was expected due to 
the fragmented nature of the extracted mtDNA (Berger and Parson 2009). Previous, 
contradictory, studies have stated that certain WGA methods can facilitate the PCR 
amplification of larger targets than the fragment size of the starting material 
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(Maciejewska, Jakubowska, and Pawłowski 2013, Ballantyne, van Oorschot, and 
Mitchell 2007). In this study, a 9.1 kb long PCR amplification on WGA material of the 
QIAGEN® REPLI-g® Single Cell kit or the Sigma-Aldrich® GenomePlex® WGA2 kit 
was not successful.  
 However, multiplex amplification of relatively short, 400-700 bp mtDNA targets 
was successful on hair shaft extracts as previously shown by E. Burnside (Burnside et al, 
2013). In forensic casework, sample material is often completely consumed in a single 
extraction process, and these DNA extracts may be of low mtDNA concentration. 
Although the hair shaft extractions performed in this study were often of sufficient 
concentration to support multiplex amplifications of the entire mtGenome, in some cases 
additional template may be necessary to support downstream processes.  
 Preliminary data from this research effort shows that the WGA kits that were 
evaluated all facilitate an augmentation in mtDNA copy number, potentially creating 
more template for subsequent analysis, albeit that some kits may be more efficient in pre-
amplifying mtDNA than others.  
 Hair shaft extracts that were multiplex amplified provided the expected sequence 
using NGS as compared to the mtDNA sequence from these donors that was derived 
using Sanger sequencing, with the exception of one 5.44% mixed position that presents 
as a possibly biological variant in one of the samples. It is unlikely that this mixed 
position is a result of the incorporation of an amplification primer that contains base 
mismatches compared to the template. Nor was this position accompanied by other low-
level mixed positions, as is expected with contamination. MtDNA sequences have been 
observed to differ throughout tissue types in an individual (Wilson et al. 1997). Since the 
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observed frequency is lower than the 10% detection threshold with Sanger sequencing, 
and this particular hair extract was sequenced with NGS only once, it is possible that the 
observed 5.44% mixed position is of biological nature. However, this cannot be 
confirmed until further sequencing is performed. 
 Error rates that result from the sequencing chemistry are low, as was evaluated by 
sequence data from the PhiX control. From these combined findings, it seems unlikely 
that mixed positions that were observed in the multiplexed PCR data originated during 
multiplexed PCR amplification or sequencing. However, as the PhiX control does not 
undergo library preparation, it cannot be excluded that the observed mixed positions are a 
result of base misincorporations introduced by the tagmentation or PCR amplification 
steps in the Illumina® Nextera® XT library preparation method. In addition, it cannot be 
confirmed that WGA product provided the template for these multiplexed PCR reactions, 
since the proper controls were not sequenced. Therefore, any mixed positions cannot 
confidently be attributed to the WGA process, and further studies are necessary to 
confirm these results. 
 The WGA product from the QIAGEN® REPLI-g® Mitochondrial DNA kit gives 
rise to a small number of low-percentage mixed positions. This could indicate that this kit 
gives the most accurate results, however it is important to note that these observations are 
based on limited data. As stated previously, it cannot be confirmed that WGA product 
provided the template for these sequencing reactions. Therefore, more studies are 
necessary to determine whether this result holds true for additional sequencing runs. 
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4.5 Concluding Remarks 
 
 To conclude, this research effort presents a method for obtaining whole mtGenome 
NGS data from reference samples, such as buccal swabs. A long PCR amplification was 
performed, after which PCR product was prepared with Illumina® Nextera® XT and 
sequenced on the Illumina® MiSeq™. This approach generated high-quality, high-
coverage data, which reflected the data obtained by Sanger sequencing.  
 In addition, preliminary data was gathered as a basis for future work targeted 
towards NGS analysis of challenging sample types. Future work in this area needs to be 
performed. More replicate experiments with all four WGA kits should be performed to 
observe their augmentation of mtDNA from hair shaft extracts. In addition, WGA 
product from the QIAGEN® REPLI-g® Single Cell kit and the Sigma-Aldrich® 
GenomePlex® WGA2 kit should be sequenced without additional multiplex PCR 
amplification, to observe whether PCR amplification is necessary for obtaining high-
coverage NGS data. Furthermore, if an NGS run is repeated with the right controls, a 
more detailed assessment can be made as to how accurately all four WGA methods 
amplify template mtDNA. 
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APPENDIX I: SANGER SEQUENCING REFERENCE DATA OF ALL DONORS 
 
 
The below tables show the reference data that was obtained with Sanger sequencing for 
all donors in this study. 
Table I.1: Sanger Sequence Donor 001 
Position rCRS Variant 
73 A G 
185 G A 
228 G A 
263 A G 
295 C T 
309.1 : C 
315.1 : C 
462 C T 
489 T C 
523 A : 
525 C : 
750 A G 
1,438 A G 
2,706 A G 
3,010 G A 
3,107 N : 
4,216 T C 
4,769 A G 
7,028 C T 
8,860 A G 
8,865 G A 
10,398 A G 
11,251 A G 
11,719 G A 
12,612 A G 
13,708 G A 
13,934 C T 
14,766 C T 
14,798 T C 
15,326 A G 
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15,452 C A 
16,069 C T 
16,093 T C/T 
16,126 T C 
16,390 G A 
Total Differences 35 
   
 
Table I.2: Sanger Sequence Donor 002 
Position rCRS Variant 
73 A G 
152 T C 
199 T C 
204 T C 
207 G A 
250 T C 
263 A G 
309.1 : C 
315.1 : C 
573.1 : C 
573.2 : C 
573.3 : C 
750 A G 
1,438 A G 
1,719 G A 
2,706 A G 
2,835 C A 
3,107 N : 
4,529 A T 
4,769 A G 
7,028 C T 
7,055 A T 
8,251 G A 
8,860 A G 
9,548 G A 
10,034 T C 
10,238 T C 
10,398 A G 
11,065 A G 
11,719 G A 
 
 
106 
12,501 G A 
12,705 C T 
13,780 A G 
14,766 C T 
15,043 G A 
15,326 A G 
15,673 A G/A 
15,758 A G 
15,924 A G 
16,074 A G 
16,129 G A 
16,145 G A 
16,223 C T 
16,391 G A 
16,519 T C 
Total Differences 45 
 
Table I.3: Sanger Sequence Donor 003 
Position rCRS Variant 
73 A G 
150 C T 
152 T C 
263 A G 
295 C T 
315.1 : C 
489 T C 
750 A G 
1,438 A G 
2,706 A G 
3,107 N : 
4,216 T C 
4,769 A G 
5,633 C T 
6,830 C A 
7,028 C T 
7,476 C T 
7,771 A G 
8,095 A G 
8,860 A G 
10,172 G A 
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10,398 A G 
11,251 A G 
11,719 G A 
12,612 A G 
12,715 A G 
13,708 G A 
14,766 C T 
15,257 G A 
15,326 A G 
15,452 C A 
15,812 G A 
16,069 C T 
16,126 T C 
16,193 C T 
16,195 T C 
16,221 C T 
16,242 C A 
16,319 G A 
16,357 T C 
16,526 G A 
Total Differences 41 
 
Table I.4: Sanger Sequence Donor 006 
Position rCRS Variant 
152 T C 
263 A G 
309.1 : C 
315.1 : C 
750 A G 
1,438 A G 
3,107 N : 
4,769 A G 
8,860 A G 
9,129 C T 
10,394 C T 
10,685 G G/A 
11,054 C T 
12,172 A G 
15,326 A G 
16,359 T C 
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16,519 T C 
Total Differences 16 
 
Table I.5: Sanger Sequence Donor 009 
Position rCRS Variant 
73 A G 
263 A G 
309.1 : C 
315.1 : C 
523 A : 
525 C : 
750 A G 
1,438 A G 
3,107 N : 
3,992 C T 
4,769 A G 
5,004 T C 
8,584 G A 
8,860 A G 
9,123 G A 
9,276 G A 
11,410 T C 
15,326 A G 
16,248 C T 
Total Differences 19 
 
Table I.6: Sanger Sequence Donor 015 
Position rCRS Variant 
73 A G 
204 T C 
263 A G 
309.1 : C 
315.1 : C 
447 C G 
489 T C 
750 A G 
1,438 A G 
1,780 T C 
2,706 A G 
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3,107 N : 
4,769 A G 
5,252 G A 
5,821 G A 
7,028 C T 
7,961 T C 
8,269 G A 
8,396 A G 
8,490 T C 
8,502 A G 
8,701 A G 
8,860 A G 
9,540 T C 
9,758 T C 
10,398 A G 
10,400 C T 
10,873 T C 
11,083 A G 
11,719 G A 
12,705 C T 
12,810 A G 
13,204 G A 
13,651 A G 
14,766 C T 
14,783 T C 
15,043 G A 
15,256 A G 
15,301 G A 
15,326 A G 
15,479 T C 
15,670 T C 
15,758 A G 
16,223 C T 
16,224 T C 
16,270 C T 
16,274 G A 
16,319 G A 
16,352 T C 
16,519 T C 
Total Differences 50 
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Table I.7: Sanger Sequence Donor 020 
Position rCRS Variant 
73 A G 
195 T A 
263 A G 
309.1 : C 
315.1 : C 
489 T C 
523 A : 
525 C : 
750 A G 
1,438 A G 
2,706 A G 
3,107 N : 
3,173 G A 
4,769 A G 
7,028 C T 
8,701 A G 
8,860 A G 
9,540 T C 
9,566 C T 
10,398 A G 
10,400 C T 
10,873 T C 
11,719 G A 
12,007 G A 
12,705 C T 
13,135 G A 
14,766 C T 
14,783 T C 
15,043 G A 
15,301 G A 
15,326 A G 
15,431 G A 
16,223 C T 
16,234 C T 
16,362 T C 
16,519 T C 
Total Differences 36 
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Table I.8: Sanger Sequence Donor 021 
Position rCRS Variant 
73 A G 
183 A G 
249 A : 
263 A G 
290 A : 
291 A : 
309.1 : C 
315.1 : C 
489 T C 
493 A G 
523 A : 
525 C : 
750 A G 
1,438 A G 
2,706 A G 
3,107 N : 
3,552 T A 
4,715 A G 
4,769 A G 
7,028 C T 
7,196 C A 
7,948 C T 
8,584 G A 
8,701 A G 
8,860 A G 
9,540 T C 
9,545 A G 
10,398 A G 
10,400 C T 
10,873 T C 
11,719 G A 
11,914 G A 
12,696 T C 
12,705 C T 
13,263 A G 
14,022 A G 
14,318 T C 
14,766 C T 
14,783 T C 
 
 
112 
15,043 G A 
15,301 G A 
15,326 A G 
15,487 A T 
16,223 C T 
16,298 T C 
16,325 T C 
16,327 C T 
16,345 A T 
Total Differences 48 
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APPENDIX II: NGS DATA FROM ALL DONORS 
 
 
The below tables show the Illumina® MiSeq™ data derived from long PCR 
amplification and NGS of all donors in this study. Data was analyzed with MiSeq™ 
Reporter 2.2 (MSR). 
 
Table II.1: Legend for interpretation of NGS data tables. 
  Expected variant from the rCRS 
 Low-level mixed position 
 
Low-level mixed position in homopolymer region 
 
Table II.2: Illumina® MiSeq™ Data Donor 001 
 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 4091 
185 SNP G->GA 99 4876 
228 SNP G->GA 9 3678 
263 SNP A->AG 100 2422 
295 SNP C->CT 100 1965 
302 Indel -/C 64 1268 
310 Indel -/C 100 989 
462 SNP C->CT 100 3535 
489 SNP T->TC 100 3038 
513 Indel CA/-- 76 2541 
750 SNP A->AG 100 6281 
1438 SNP A->AG 100 8236 
2706 SNP A->AG 100 2373 
3010 SNP G->GA 100 5558 
3106 Indel N/- 93 5672 
4216 SNP T->TC 100 8719 
4769 SNP A->AG 100 8988 
7028 SNP C->CT 99 6746 
8860 SNP A->AG 100 8540 
 
 
114 
8865 SNP G->GA 100 8752 
10398 SNP A->AG 100 3272 
11251 SNP A->AG 100 4863 
11719 SNP G->GA 100 5384 
12612 SNP A->AG 100 3561 
13708 SNP G->GA 100 1600 
13934 SNP C->CT 100 5167 
14766 SNP C->CT 100 5021 
14798 SNP T->TC 100 5227 
15326 SNP A->AG 100 10169 
15452 SNP C->CA 100 11480 
16069 SNP C->CT 100 8825 
16093 SNP T->TC 92 10463 
16126 SNP T->TC 100 11615 
16390 SNP G->GA 100 11826 
 
Table II.3: Illumina® MiSeq™ Data Donor 002 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 11289 
152 SNP T->TC 100 16694 
199 SNP T->TC 100 10632 
204 SNP T->TC 100 9558 
207 SNP G->GA 100 9341 
250 SNP T->TC 100 5959 
263 SNP A->AG 100 4512 
302 Indel -/C 91 1755 
310 Indel -/C 100 2043 
567 Indel ---/CCC 49 1781 
750 SNP A->AG 100 18207 
1438 SNP A->AG 100 25567 
1719 SNP G->GA 100 24450 
2706 SNP A->AG 100 6461 
2835 SNP C->CA 100 11764 
3106 Indel N/- 94 10710 
4529 SNP A->AT 100 10163 
4769 SNP A->AG 100 11051 
7028 SNP C->CT 99 13846 
7055 SNP A->AT 100 12759 
8251 SNP G->GA 100 9854 
8843 SNP T->TC 2 16098 
8860 SNP A->AG 100 15077 
9548 SNP G->GA 100 9238 
10034 SNP T->TC 100 7260 
10238 SNP T->TC 100 6587 
 
 
115 
10398 SNP A->AG 100 8828 
11065 SNP A->AG 100 11494 
11719 SNP G->GA 100 14204 
12501 SNP G->GA 100 8863 
12705 SNP C->CT 100 11234 
13780 SNP A->AG 100 4520 
14766 SNP C->CT 100 12300 
15043 SNP G->GA 100 16826 
15326 SNP A->AG 100 28723 
15673 SNP A->AG 83 26461 
15758 SNP A->AG 100 26543 
15924 SNP A->AG 100 20390 
16074 SNP A->AG 100 20066 
16129 SNP G->GA 99 23467 
16145 SNP G->GA 1 24327 
16223 SNP C->CT 99 31446 
16391 SNP G->GA 100 31781 
16519 SNP T->TC 100 11915 
 
Table II.4: Illumina® MiSeq™ Data Donor 003 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 12352 
150 SNP C->CT 100 18709 
152 SNP T->TC 100 18589 
263 SNP A->AG 100 6161 
295 SNP C->CT 100 4621 
310 Indel -/C 100 2800 
489 SNP T->TC 100 6026 
750 SNP A->AG 100 19878 
1438 SNP A->AG 100 25184 
2706 SNP A->AG 100 6989 
3106 Indel N/- 94 11711 
4216 SNP T->TC 100 13823 
4769 SNP A->AG 100 12363 
5633 SNP C->CT 100 7407 
6830 SNP C->CA 100 16315 
7028 SNP C->CT 100 14728 
7476 SNP C->CT 100 7281 
7771 SNP A->AG 100 13124 
8095 SNP A->AG 100 11163 
8860 SNP A->AG 100 16142 
10172 SNP G->GA 100 5235 
10398 SNP A->AG 100 7142 
11251 SNP A->AG 100 11689 
 
 
116 
11719 SNP G->GA 100 11450 
12612 SNP A->AG 100 9729 
12715 SNP A->AG 100 10944 
13708 SNP G->GA 100 3581 
14766 SNP C->CT 100 9727 
15257 SNP G->GA 100 20862 
15326 SNP A->AG 100 25206 
15452 SNP C->CA 100 24965 
15812 SNP G->GA 100 24231 
16069 SNP C->CT 100 21264 
16126 SNP T->TC 100 25162 
16193 SNP C->CT 100 31445 
16195 SNP T->TC 100 32680 
16221 SNP C->CT 99 30154 
16242 SNP C->CA 100 31311 
16319 SNP G->GA 99 23878 
16357 SNP T->TC 100 27890 
16526 SNP G->GA 100 9901 
 
Table II.6: Illumina® MiSeq™ Data Donor 006 
Position 
Variant 
Type Call Frequency Depth 
152 SNP T->TC 97 24389 
263 SNP A->AG 1 5809 
302 Indel -/C 54 2264 
310 Indel -/C 84 2365 
750 SNP A->AG 100 26627 
1438 SNP A->AG 100 34013 
3106 Indel N/- 94 15518 
4769 SNP A->AG 100 15148 
8860 SNP A->AG 100 18638 
9129 SNP C->CT 100 13532 
10394 SNP C->CT 100 9577 
10685 SNP G->GA 12 14805 
11054 SNP C->CT 100 12260 
12172 SNP A->AG 100 13435 
15326 SNP A->AG 100 32190 
16359 SNP T->TC 100 31132 
16519 SNP T->TC 100 14535 
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Table II.6: Illumina® MiSeq™ Data Donor 009 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 14785 
215 SNP A->AG 4 13661 
263 SNP A->AG 100 7286 
302 Indel -/C 90 2938 
310 Indel -/C 100 3204 
513 Indel CA/-- 81 7516 
750 SNP A->AG 100 24436 
1438 SNP A->AG 100 29430 
3106 Indel N/- 94 13618 
3992 SNP C->CT 100 15232 
4769 SNP A->AG 100 14626 
5004 SNP T->TC 100 16469 
8584 SNP G->GA 100 11174 
8860 SNP A->AG 100 18337 
9123 SNP G->GA 100 22702 
9276 SNP G->GA 100 16198 
11410 SNP T->TC 100 17430 
15326 SNP A->AG 100 30673 
16248 SNP C->CT 100 34358 
 
Table II.7: Illumina® MiSeq™ Data Donor 015 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 15397 
204 SNP T->TC 100 15078 
263 SNP A->AG 100 7112 
302 Indel -/C 91 2810 
310 Indel -/C 100 3052 
447 SNP C->CG 100 6649 
489 SNP T->TC 100 5794 
750 SNP A->AG 100 23475 
921 SNP T->TC 2 25183 
1438 SNP A->AG 100 30130 
1780 SNP T->TC 100 25359 
2706 SNP A->AG 100 7247 
3106 Indel N/- 95 12924 
4769 SNP A->AG 100 13278 
5252 SNP G->GA 100 13155 
5821 SNP G->GA 100 9269 
7028 SNP C->CT 99 15464 
7961 SNP T->TC 100 15979 
 
 
118 
8269 SNP G->GA 100 11004 
8396 SNP A->AG 100 10300 
8490 SNP T->TC 100 10724 
8502 SNP A->AG 100 10297 
8701 SNP A->AG 100 16737 
8860 SNP A->AG 100 17238 
9540 SNP T->TC 100 13209 
9758 SNP T->TC 100 10955 
10398 SNP A->AG 100 8932 
10400 SNP C->CT 100 9012 
10873 SNP T->TC 100 7475 
11083 SNP A->AG 100 13349 
11719 SNP G->GA 100 15239 
12705 SNP C->CT 100 12410 
12810 SNP A->AG 100 11792 
13204 SNP G->GA 100 16214 
13651 SNP A->AG 100 4511 
14766 SNP C->CT 100 12807 
14783 SNP T->TC 100 13259 
15043 SNP G->GA 100 17550 
15256 SNP A->AG 100 25324 
15301 SNP G->GA 100 27441 
15326 SNP A->AG 100 31776 
15479 SNP T->TC 100 29744 
15670 SNP T->TC 100 31170 
15758 SNP A->AG 100 30079 
16223 SNP C->CT 100 32348 
16224 SNP T->TC 100 34657 
16270 SNP C->CT 100 33167 
16274 SNP G->GA 99 32488 
16319 SNP G->GA 100 27380 
16352 SNP T->TC 100 32237 
16519 SNP T->TC 100 13959 
 
Table II.8: Illumina® MiSeq™ Data Donor 020 
Position 
Variant 
Type Call Frequency Depth 
73 SNP A->AG 100 12299 
195 SNP T->TA 100 13177 
263 SNP A->AG 100 4882 
302 Indel -/C 82 2057 
310 Indel -/C 100 2069 
489 SNP T->TC 100 3800 
513 Indel CA/-- 84 4132 
 
 
119 
750 SNP A->AG 100 17697 
1438 SNP A->AG 100 23124 
2706 SNP A->AG 100 6809 
3106 Indel N/- 95 11981 
3173 SNP G->GA 100 10440 
4769 SNP A->AG 100 12677 
6734 SNP G->GA 2 15873 
7028 SNP C->CT 100 15055 
8701 SNP A->AG 100 15661 
8860 SNP A->AG 100 16479 
9540 SNP T->TC 100 10361 
9566 SNP C->CT 100 8561 
10398 SNP A->AG 100 5759 
10400 SNP C->CT 100 5839 
10873 SNP T->TC 100 4543 
11198 SNP A->AT 5 9035 
11719 SNP G->GA 100 10134 
12007 SNP G->GA 100 10171 
12705 SNP C->CT 100 7986 
13135 SNP G->GA 100 7264 
14536 SNP A->AT 5 7899 
14766 SNP C->CT 100 8504 
14783 SNP T->TC 100 8880 
15043 SNP G->GA 100 12055 
15301 SNP G->GA 100 20890 
15326 SNP A->AG 100 24217 
15431 SNP G->GA 100 20827 
16223 SNP C->CT 100 27425 
16234 SNP C->CT 100 28294 
16362 SNP T->TC 100 26053 
16519 SNP T->TC 100 10670 
 
Table II.9: Illumina® MiSeq™ Data Donor 021 
Position 
Variant 
Type Call Frequency 
73 SNP A->AG 100 
183 SNP A->AG 100 
247 Indel A/- 88 
263 SNP A->AG 1 
285 Indel AA/-- 76 
302 Indel -/C 100 
310 Indel -/C 100 
489 SNP T->TC 100 
493 SNP A->AG 100 
 
 
120 
513 Indel CA/-- 83 
750 SNP A->AG 100 
1438 SNP A->AG 100 
2706 SNP A->AG 100 
3106 Indel N/- 94 
3421 SNP G->GA 2 
3552 SNP T->TA 100 
4715 SNP A->AG 100 
4769 SNP A->AG 100 
7028 SNP C->CT 100 
7196 SNP C->CA 100 
7948 SNP C->CT 100 
8584 SNP G->GA 100 
8701 SNP A->AG 100 
8860 SNP A->AG 100 
9540 SNP T->TC 100 
#9545 SNP A->AG 100 
10398 SNP A->AG 100 
10400 SNP C->CT 100 
10873 SNP T->TC 100 
11719 SNP G->GA 100 
11914 SNP G->GA 100 
12696 SNP T->TC 100 
12705 SNP C->CT 100 
13263 SNP A->AG 100 
14022 SNP A->AG 100 
14318 SNP T->TC 100 
14766 SNP C->CT 100 
14783 SNP T->TC 100 
15043 SNP G->GA 100 
15301 SNP G->GA 100 
15326 SNP A->AG 100 
15487 SNP A->AT 100 
16223 SNP C->CT 100 
16298 SNP T->TC 100 
16325 SNP T->TC 100 
16327 SNP C->CT 100 
16345 SNP A->AT 100 
 
